CA2264243C - Glp-1 derivatives - Google Patents

Glp-1 derivatives Download PDF

Info

Publication number
CA2264243C
CA2264243C CA002264243A CA2264243A CA2264243C CA 2264243 C CA2264243 C CA 2264243C CA 002264243 A CA002264243 A CA 002264243A CA 2264243 A CA2264243 A CA 2264243A CA 2264243 C CA2264243 C CA 2264243C
Authority
CA
Canada
Prior art keywords
glp
xaa
derivative
arg
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002264243A
Other languages
French (fr)
Other versions
CA2264243A1 (en
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2264243(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CA2468374A priority Critical patent/CA2468374C/en
Publication of CA2264243A1 publication Critical patent/CA2264243A1/en
Application granted granted Critical
Publication of CA2264243C publication Critical patent/CA2264243C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Medicinal Preparation (AREA)

Abstract

Derivatives of GLP-1 and analogues thereof having a lipophilic substituent have interesting pharmacological properties, in particular they have a more protracted profile of action than GLP-1(7-37).

Description

101520253035CA 02264243 1999-02-25W0 93/08871 PCT/DK97/00340GLP-1 DERIVATIVESFIELD OF THE INVENTIONThe present invention relates to novel derivatives of human glucagon-like peptide-1 (GLP-1)and fragments thereof and analogues of such fragments which have a protracted profile ofaction and to methods of making and using them.BACKGROUND OF THE INVENTIONPeptides are widely used in medical practice, and since they can be produced byrecombinant DNA technology it can be expected that their importance will increase also inthe years to come. When native peptides or analogues thereof are used in therapy it isgenerally found that they have a high clearance. A high clearance of a therapeutic agent isinconvenient in cases where it is desired to maintain a high blood level thereof over aprolonged period of time since repeated administrations will then be necessary. Examples ofpeptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin,calcitonin, insulin, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, insulin-likegrowth factor-1, insulin-like growth factor—2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin,somatostatin. somatotropin, somatomedin, parathyroid hormone, thrombopoietin,erythropoietin, hypothalarnic releasing factors. prolactin, thyroid stimulating hormones,endorphins, enkephalins. vasopressin, oxytocin. opiods and analogues thereof, superoxidedismutase, interferon, asparaginase, arginase, arginine deaminase, adenosine deaminaseand ribonuclease. in some cases it is possible to influence the release profile of peptides byapplying suitable pharmaceutical compositions, but this approach has various shortcomingsand is not generally applicable.The hormones regulating insulin secretion belong to the so-called enteroinsular axis,designating a group of hormones, released from the gastrointestinal mucosa in responseto the presence and absorption of nutrients in the gut, which promote an early andpotentiated release of insulin. The enhancing effect on insulin secretion, the so—calledincretin effect, is probably essential for a normal glucose tolerance. Many of thegastrointestinal hormones, includino oastrin and secretin (cholecystokinin is not101520253035CA 02264243 1999-02-25W0 98/08871 PCT/DK97/00340insulinotropic in man), are insulinotropic, but the only physiologically important ones, thosethat are responsible for the incretin effect, are the glucose—dependent insulinotropicpolypeptide, GIP, and glucagon-like peptide-1 (GLP-1). Because of its insulinotropic effect,GIP, isolated in 1973 (1) immediately attracted considerable interest among diabetologists.However, numerous investigations carried out during the following years clearly indicatedthat a defective secretion of GlP was not involved in the pathogenesis of insulin dependentdiabetes mellitus (IDDM) or non insulin-dependent diabetes mellitus (NIDDM) (2).Furthermore, as an insulinotropic hormone, GIP was found to be almost ineffective inNIDDM (2). The other incretin hormone, GLP-1 is the most potent insulinotropic substanceknown (3). Unlike GIP, it is surprisingly effective in stimulating insulin secretion in NIDDMpatients. In addition, and in contrast to the other insulinotropic hormones (perhaps with theexception of secretin) it also potently inhibits glucagon secretion. Because of these actionsit has pronounced blood glucose lowering effects particularly in patients with NIDDM.GLP-1, a product of the proglucagon (4), is one of the youngest members of the secretin-VlP family of peptides, but is already established as an important gut hormone withregulatory function in glucose metabolism and gastrointestinal secretion and metabolism(5). The glucagon gene is processed differently in the pancreas and in the intestine. In thepancreas (9), the processing leads to the formation and parallel secretion of 1) glucagonitself, occupying positions 33-61 of proglucagon (PG); 2) an N-terminal peptide of 30amino acids (PG (1-30)) often called glicentin-related pancreatic peptide, GRPP (10, 11);3) a hexapeptide corresponding to PG (64-69); 4) and, finally, the so-called majorproglucagon fragment (PG (72-158)), in which the two glucagon-like sequences are buried(9). Glucagon seems to be the only biologically active product. In contrast, in the intestinalmucosa, it is glucagon that is buried in a larger molecule, while the two glucagon-likepeptides are formed separately (8). The following products are formed and secreted inparallel: 1) glicentin, corresponding to PG (1-69), with the glucagon sequence occupyingresidues Nos. 33-61 (12); 2) GLP-1(7-36)amide (PG (78-107))amide (13), not as originallybelieved PG (72-107)amide or 108, which is inactive). Small amounts of C-terminallyglycine-extended but equally bioactive GLP-1(7-37), (PG (78-108)) are also formed (14);3) intervening peptide-2 (PG (111-122)amide) (15); and 4) GLP-2 (PG (126-158)) (15, 16).A fraction of glicentin is cleaved further into GRPP (PG (1-30)) and oxyntomodulin (PG(33-69)) (17, 18). Of these peptides, GLP-1, has the most conspicuous biological activities.Being secreted in parallel with glicentin/enteroglucagon, it follows that the many studies ofenteroglucagon secretion (6, 7) to some extent also apply to GLP-1 secretion, but GLP-1is metabolised more quickly with a plasma half-life in humans of 2 min (19). Carbohydrate101520253035CA 02264243 1999-02-25W0 93/03371 PCT/DK97/00340or fat-rich meals stimulate secretion (20), presumably as a result of direct interaction of yetunabsorbed nutrients with the microvilli of the open-type L-cells of the gut mucosa.Endocrine or neural mechanisms promoting GLP-1 secretion may exist but have not yetbeen demonstrated in humans.The incretin function of GLP-1(29-31) has been clearly illustrated in experiments with theGLP-1 receptor antagonist, exendin 9-39, which dramatically reduces the incretin effectelicited by oral glucose in rats (21, 22). The hormone interacts directly with the B-cells viathe GLP-1 receptor (23) which belongs to the glucagonNlP/calcitonin family of G-protein-coupled 7-transmembrane spanning receptors. The importance of the GLP-1 receptor inregulating insulin secretion was illustrated in recent experiments in which a targeteddisruption of the GLP-1 receptor gene was carried out in mice. Animals homozygous forthe disruption had greatly deteriorated glucose tolerance and fasting hyperglycaemia, andeven heterozygous animals were glucose intolerant (24). The signal transductionmechanism (25) primarily involves activation of adenylate cyclase, but elevations ofintracellular Ca2+ are also essential (25, 26). The action of the hormone is best describedas a potentiation of glucose stimulated insulin release (25), but the mechanism thatcouples giucose and GLP-1 stimulation is not known. it may involve a calcium-inducedcalcium release (26, 27). As already mentioned, the insulinotropic action of GLP-1 ispreserved in diabetic B-cells. The relation of the latter to its ability to convey "glucosecompetence" to isolated insulin-secreting cells (26. 28), which respond poorly to glucose orGLP-1 alone, but fully to a combination of the two, is also not known. Equally importantly.however, the hormone also potently inhibits glucagon secretion (29). The mechanism isnot known, but seems to be paracrine, via neighbouring insulin or somatostatin cells (25).Also the glucagonostatic action is glucose-dependent, so that the inhibitory effectdecreases as blood glucose decreases. Because of this dual effect, if the plasma GLP-1concentrations increase either by increased secretion or by exogenous infusion the molarratio of insulin to glucagon in the blood that reaches the liver via the portal circulation isgreatly increased, whereby hepatic glucose production decreases (30). As a result bloodglucose concentrations decrease. Because of the glucose dependency of the insulinotropicand glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone,therefore, does not cause hypoglycaemia regardless of dose (31). The effects arepreserved in patients with diabetes mellitus (32), in whom infusions of slightlysupraphysiological doses of GLP-1 may completely normalise blood glucose values inspite of poor metabolic control and secondary failure to sulphonylurea (33). Theimportance of the glucagonostatic effect is illustrated by the finding that GLP-1 also lowersblood glucose in type-1 diabetic patients without residual (3—cell secretory capacity (34).101520253035CA 02264243 1999-02-25W0 98/08871 PCT/DK97/00340In addition to its effects on the pancreatic islets, GLP-1 has powerful actions on thegastrointestinal tract. amounts, GLP-1 potently inhibitspentagastrin-induced as well as meal-induced gastric acid secretion (35, 36). it alsoInfused in physiologicalinhibits gastric emptying rate and pancreatic enzyme secretion (36). Similar inhibitoryeffects on gastric and pancreatic secretion and motility may be elicited in humans uponperfusion of the ileum with carbohydrate- or lipid-containing solutions (37, 38).Concomitantly, GLP-1 secretion is greatly stimulated, and it has been speculated thatGLP-1 may be at least partly responsible for this so-called "ileal-brake" effect (38). In fact,recent studies suggest that, physiologically, the ileal-brake effects of GLP-1 may be moreimportant than its effects on the pancreatic islets. Thus, in dose response studies GLP-1influences gastric emptying rate at infusion rates at least as low as those required toinfluence islet secretion (39).GLP-1 seems to have an effect on food intake. lntraventricular administration of GLP-1profoundly inhibits food intake in rats (40, 42). This effect seems to be highly specific.Thus, N-terminally extended GLP-1 (PG 72-107)amide is inactive and appropriate dosesof the GLP-1 antagonist, exendin 9-39, abolish the effects of GLP-1 (41). Acute, peripheraladministration of GLP-1 does not inhibit food intake acutely in rats (41, 42). However, itremains possible that GLP-1 secreted from the intestinal L-cells may also act as a satietysignal.Not only the insulinotropic effects but also the effects of GLP-1 on the gastrointestinal tractare preserved in diabetic patients (43), and may help curtailing meal-induced glucoseexcursions, but, more importantly, may also influence food intake. Administeredintravenously, continuously for one week, GLP-1 at 4 ng/kg/min has been demonstrated todramatically improve glycaemic control in NIDDM patients without significant side effects(44). The peptide is fully active after subcutaneous administration (45), but is rapidlydegraded mainly due to degradation by dipeptidyl peptidase lV-like enzymes (46, 47).The amino acid sequence of GLP-1 is given i.a. by Schmidt et al. (Diabetologia 28 704-707(1985). Although the interesting pharmacological properties of GLP-1(7-37) and analoguesthereof have attracted much attention in recent years only little is known about thestructure of these molecules. The secondary structure of GLP-1 in micelles has beendescribed by Thorton et al. (Biochemistry 33 3532-3539 (1994)), but in normalsolution,GLP-1 is considered a very flexible molecule. Surprisingly, we found thatderivatisation of this relatively small and very flexible molecule resulted in compounds101520253035CA 02264243 1999-02-25wo 93/03371 PCT/DK97l00340whose plasma profile were highly protracted and still had retained activity.GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful i.a. in thetreatment of type 1 and type 2 diabetes. However, the high clearance limits the usefulness ofthese compounds, and thus there still is a need for improvements in this field. Accordingly, itis one object of the present invention to provide derivatives of GLP-1 and analogues thereofwhich have a protracted profile of action relative to GLP-1(7-37). It is a further object of theinvention to provide derivatives of GLP-1 and analogues thereof which have a lowerclearance than GLP-1(7-37). it is a further object of the invention to provide a pharmaceuticalcomposition comprising a compound according to the invention and to use a compound ofthe invention to provide such a composition. Also, it is an object of the present invention toprovide a method of treating insulin dependent and non-insulin dependent diabetes mellitus.References.1. Pederson RA. Gastric inhibitory Polypeptide. in Walsh JH, Dockray GJ (eds) Gutpeptides: Biochemistry and Physiology. Raven Press, New York 1994, pp. 217259.2. Krarup T. lmmunoreactive gastric inhibitory polypeptide. Endocr Rev 1988;93:122-134.3. Grskov C. Glucagon-like peptide-1. a new hormone of the enteroinsular axis.Diabetologia 1992; 35:701-711.4. Bell Gl, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication anddivergence in the human preproglucagon gene. Nature 1983; 304: 368-371.5. Holst JJ. Glucagon-like peptide-1 (GLP-1) - a newly discovered GI hormone.Gastroenterology 1994; 107: 1848-1855.6. Holst JJ. Gut glucagon, enteroglucagon, gut GLl,Gastroenterology 1983;84:1602-1613.glicentin - current status.7. Holst JJ, Qrskov C. Glucagon and other proglucagon-derived peptides. in Welsh JH,Dockray GJ, eds. Gut peptides: Biochemistry and Physiology. Raven Press, New York,.. .~.._,...........i................A...:....-........a......_.... ........ . ,.,.. .............s . ,.‘IO15202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/00340pp. 305-340, 1993.8. flrskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV.Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, aresecreted separately from the pig small intestine, but not pancreas. Endocrinology1986;119:1467-1475.9. Holst JJ. Bersani M, Johnsen AH, Kofod H, Hartmann B, Grskov C. Proglucagonprocessing in porcine and human pancreas. J Biol Chem, 1994; 269: 18827-1883.10. Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon andglucagon in the porcine pancreas. Nature 1981; 289: 514-516.11. Thim L, Moody AJ, Purification and chemical characterisation of a glicentin-relatedpancreatic peptide (proglucagon fragment) from porcine pancreas. Biochim BiophysActa 1982;703:134-141.12. Thim L, Moody AJ. The primary structure of glicentin (proglucagon). Regul Pept1981;2:139-151.13. Qrskov C, Bersani M, Johnsen AH, Hzjrup P, Holst JJ. Complete sequences ofglucagon-like peptide-1 (GLP-1) from human and pig small intestine. J. Biol. Chem.1989;264:12826-12829.14. Qrskov C, Rabenhrzij L, Kofod H, Wettergren A, Holst JJ. Production and secretion ofamidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1991;43: 535-539.15. Buhl T, Thim L, Kofod H, Qrskov C, Harling H, & Holst JJ: Naturally occurring productsof proglucagon 111-160 in the porcine and human small intestine. J. Biol. Chem.1988;263:8621-8624.16. Qrskov C, Buhl T, Rabenhoj L, Kofod H, Holst JJ: Carboxypeptidase-B-like processingof the C-terminus of glucagon-like peptide-2 in pig and human small intestine. FEBS1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/00340letters, 1989;247:193-106.17. Holst JJ. Evidence that enteroglucagon (ll) is identical with the C-terminal sequence(residues 33-69) of glicentin. Biochem J. 1980;187:337—343.18. Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation ofglucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum.Characterisation of the peptide. FEBS Lett 1982;146:79-86.19. Qrskov C, Wettergren A, Hoist JJ. The metabolic rate and the biological effects ofGLP-1 7—36amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes1993;42:658-661.20. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-likepeptide-1 (7-36)amide and glucose-dependent insuiinotropic polypeptide secretion inresponse to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.J Endocrinol 1993; 138: 159-166.21. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by theglucagon-like peptide-1 receptor antagonist exendin (9-39)amide. Diabetes 1995; 44:16-19.22. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei M, Bloom SR. Glucagon-like peptide-1is a physiological incretin in rat. J. Clin. Invest. 1995; 95: 417-421.23. Thorens B. Expression cloning of the pancreatic b cell receptor for the gluco-incretinhormone glucagon-like peptide 1. Proc Natl Acad Sci 1992;89:8641-4645.24. Scrocchi L, Auerbach AB, Joyner AL, Drucker DJ. Diabetes in mice with targeteddisruption of the GLP-1 receptor gene. Diabetes 1996; 45: 21A.25. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormonesglucagon-like peptide-I (GLP-1) and glucose-dependent insulin releasing polypeptide(GIP). Endocrine Reviews. 1995; 16: 390-410..,...d.....J.........._................................... .1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034026. Gromada J, Dissing S, Bokvist K, Renstrbm E, Frokjaer-Jensen J, Wulff BS, RorsmanP. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting bTC3-cellsby enhancement of intracellular calcium mobilisation. Diabetes 1995; 44: 767-774.27. Holz GG, Leech CA, Habener JF. Activation of a cAMP-regulated Ca“-signalingpathway in pancreatic B-cells by the insulinotropic hormone glucagon-like peptide-1. JBiol Chem, 1996; 270: 17749-17759.28. Holz GG, Ktihltreiber WM, Habener JF. Pancreatic beta-cells are rendered glucosecompetent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature1993;361:362-365.29. Qrskov C, Holst JJ, Nielsen OV: Effect of truncated giucagon—iike peptide-1(proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum andstomach. Endocrinology 1988;123:2009-2013.30. Hvidberg A, Toft Nielsen M, Hilsted J, Qrskov C, Holst JJ. Effect of giucagon—iikepeptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.Metabolism 1994;43:104-108.31. Qualmann C, Nauck M, Holst JJ, Zrskov C, Creutzfeldt W. lnsulinotropic actions ofintravenous glucagon-like peptide-1 [7-36 amide] in the fasting state in healthy subjects.Acta Diabetologica, 1995; 32: 13-16.32. Nauck MA, Heimesaat MM, Qrskov C, Holst JJ, Ebert R, Creutzfeldt W. Preservedincretin activity of GLP-1(7-36amide) but not of synthetic human GlP in patients withtype 2-diabetes mellitus. J Clin Invest 1993;91:301-307.33. Nauck MA, Kleine N, Qrskov C, Holst JJ, Willms B, Creutzfeldt W. Normalisation offasting hyperglycaemia by exogenous GLP-1(7-36amide) in type 2-diabetic patients.Diabetologia 1993;36:741-744.34. Creutzfeldt W, Kleine N, Willms B, Erskov C, Holst JJ, Nauck MA. GlucagonostaticCA 02264243 1999-02-25WO 98/08871 PCTIDK97/00340actions and reduction of fasting hyperglycaemia by exogenous glucagon-liem,peptide-1(7-36amide) in type I diabetic patients. Diabetes Care 1996; 19: 580-586.35. Schjoldager BTG, Mortensen PE, Christiansen J, Qirskov C, Holst JJ. GLP-15 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon,inhibit gastric acid secretion in man. Dig. Dis. Sci. 1989; 35:703-708.36. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ.Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions10 in man. Dig Dis Sci 1993;38:665-673.37. Layer P, Holst JJ, Grandt D, Goebell H: lleal release of glucagon-like peptide-1(GLP-1): association with inhibition of gastric acid in humans. Dig Dis Sci 1995; 40:1074-1082.1538. Layer P, Holst JJ. GLP-1: A humoral mediator of the lleal brake in humans? Digestion1993; 54: 385-386.39. Nauck M, Ettler R, Niedereichholz U, Zrskov C, Holst JJ. Schmiegel W. Inhibition of20 gastric emptying by GLP-1(7-36 amide) or (7-37): effects on postprandial glycaemiaand insulin secretion. Abstract. Gut 1995; 37 (suppl. 2): A124.40. Schick RR, vorm Walde T, Zimmermann JP, Schusdziarra V, Classen M.Glucagon-like peptide 1 - a novel brain peptide involved in feeding regulation. in25 Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds.) Obesity inEurope. John Libbey & Company ltd, 1994; pp. 363-367.41. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Mialler M, SheikhS. Brain GLP-1(7-36) amide receptors play a major role in regulation of food and water30 intake. Am. J. Physiol., 1996, in press.42. Turton MD, O'Shea D, Gunn l, Beak SA, Edwards CMB, Meeran K, et al. A role forglucagon-like peptide-1 in the regulation of feeding. Nature 1996; 379: 6972.1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97/003401043. Willms B, Werner J, Creutzfeldt W, Qrskov C, Holst JJ, Nauck M. Inhibition of gastricemptying by glucagon-like peptide-1 (7-36 amide) in patients with type-2-diabetesmellitus. Diabetologia 1994; 37, suppl.1: A118.44. Larsen J, Jallad N, Damsbo P. One-week continuous infusion of GLP-1(7-37) improvesglycaemic control in NIDDM. Diabetes 1996; 45, suppl. 2: 233A.45. Ritzel R, Qrskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, andglucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection inhealthy volunteers. Dose-response relationships. Diabetologia 1995; 38: 720-725.46. Deacon CF, Johnsen AH, Holst JJ. Degradation of giucagon-like peptide-1 by humanplasma in vitro yields an N-terminally truncated peptide that is a major endogenousmetabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.47. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. 1995. Bothsubcutaneous and intravenously administered glucagon~like peptide-1 are rapidlydegraded from the amino terminus in type ll diabetic patients and in healthy subjects.Diabetes 44: 1126-1131.SUMMARY OF THE INVENTIONHuman GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which issynthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. Processingof preproglucagon to give GLP-1(7—36)amide, GLP-1(7-37) and GLP-2 occurs mainly in theL—cells. A simple system is used to describe fragments and analogues of this peptide. Thus,for example, Gly°-GLP-1(7-37) designates a fragment of GLP-1 formally derived from GLP-1by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring aminoacid residue in position 8 (Ala) by Gly. Similarly, l_ys3“(N‘-tetradecanoyl)-GLP-1(7-37)designates GLP-1(7-37) wherein the e-amino group of the Lys residue in position 34 hasbeen tetradecanoylated. Where reference in this text is made to C-terminally extended GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, theoptional amino acid residue in position 39 is also Arg unless otherwise indicated and the1015202530CA 02264243 1999-02-25wo 98/08871 PCT/DK97/0034011optional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-terminally extended analogue extends to position 41, 42, 43, 44 or '45, the amino acidsequence of this extension is as in the corresponding sequence in human preproglucagonunless othen/vise indicated.in its broadest aspect, the present invention relates to derivatives of GLP-1 and analoguesthereof. The derivatives according to the invention have interesting pharmacologicalproperties, in particular they have a more protracted profile of action than the parentpeptides.In the present text, the designation “an analogue" is used to designate a peptide wherein oneor more amino acid residues of the parent peptide have been substituted by another aminoacid residue and/or wherein one or more amino acid residues of the parent peptide havebeen deleted and/or wherein one or more amino acid residues have been added to theparent peptide. Such addition can take place either at the N-terminal end or at the C-terminalend of the parent peptide or both.The term "derivative" is used in the present text to designate a peptide in which one or moreof the amino acid residues of the parent peptide have been chemically modified, e.g. byalkylation, acylation, ester formation or amide formation.The term “a GLP-1 derivative” is used in the present text to designate a derivative of GLP-1or an analogue thereof. in the present text, the parent peptide from which such a derivative isformally derived is in some places referred to as the "GLP-1 moiety” of the derivative.in a preferred embodiment, as described in Claim 1, the present invention relates to a GLP-1derivative wherein at least one amino acid residue of the parent peptide has a lipophilicsubstituent attached with the proviso that if only one lipophilic substituent is present and thissubstituent is attached to the N-terminal or to the C-terminal amino acid residue of the parentpeptide then this substituent is an alkyl group or a group which has an co-carboxylic acidgroup.In another preferred embodiment, as described in Claim 2, the present invention relates to aGLP-1 derivative having only one lipophilic substituent.1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97l0034012in another preferred embodiment, as described in Claim 3, the present invention relates to aGLP-1 derivative having only one lipophilic substituent which substituent is an alkyl group ora group which has an co-carboxylic acid group and is attached to the N-terminal amino acidresidue of the parent peptide.in another preferred embodiment, as described in Claim 4, the present invention relates to aGLP-1 derivative having only one lipophilic substituent which substituent is an alkyl group ora group which has an co-carboxylic acid group and is attached to the C-terminal amino acidresidue of the parent peptide.in another preferred embodiment, as described in Claim 5, the present invention relates to aGLP-1 derivative having only one llpophilic substituent which substituent can be attached toany one amino acid residue which is not the N-terminal or C-terminal amino acid residue ofthe parent peptide.In another preferred embodiment, as described in Claim 6, the present invention relates to aGLP-1 derivative wherein two lipophilic substituents are present.In another preferred embodiment, as described in Claim 7. the present invention relates to aGLP-1 derivative wherein two lipophilic substituents are present, one being attached to theN-terminal amino acid residue while the other is attached to the C-terminal amino acidresidue.In another preferred embodiment, as described in Claim 8, the present invention relates to aGLP-1 derivative wherein two lipophilic substituents are present, one being attached to theN-terminal amino acid residue while the other is attached to an amino acid residue which isnot N-terminal or the C-terminal amino acid residue.in another preferred embodiment, as described in Claim 9, the present invention relates to aGLP-1 derivative wherein two lipophilic substituents are present, one being attached to theC-terminal amino acid residue while the other is attached to an amino acid residue which isnot the N-terminal or the C-terminal amino acid residue. 1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034013lnfurther preferred embodiment, as described in Claim 10, the present invention relates to aderivative of GLP-1(7-C), wherein C is selected from the group comprising 38, 39, 40, 41, 42,43, 44 and 45 which derivative has just one Iipophilic substituent which is attached to the C-terminal amino acid residue of the parent peptide.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the Iipophilic substituent comprises from 4 to 40 carbon atoms, more preferred from8 to 25 carbon atoms.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to an amino acid residue in such a way that acarboxyl group of the lipophilic substituent forms an amide bond with an amino group of theamino acid residue.in a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to an amino acid residue in such a way that anamino group of the lipophilic substituent forms an amide bond with a carboxyl group of theamino acid residue.in a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent - optionally via a spacer - is attached to the e-amino group ofa Lys residue contained in the parent peptide.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer whichis an unbranched alkane on,m-dicarboxylic acid group having from 1 to 7 methylene groups,preferably two methylene groups which spacer forms a bridge between an amino group ofthe parent peptide and an amino group of the lipophilic substituent.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer which1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97/00340‘I4is an amino acid residue except Cys, or a dipeptide such as Gly-Lys. In the present text, theexpression “a dipeptide such as Gly-Lys" is used to designate a dipeptide wherein the C-terminal amino acid residue is Lys, His or Trp, preferably Lys, and wherein the N-terminalamino acid residue is selected from the group comprising Ala, Arg, Asp, Asn, Gly, Glu, Gin,lie, Leu, Val, Phe and Pro.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer whichis an amino acid residue except Cys, or is a dipeptide such as Gly-Lys and wherein acarboxyl group of the parent peptide forms an amide bond with an amino group of a Lysresidue or a dipeptide containing a Lys residue, and the other amino group of the Lys residueor a dipeptide containing a Lys residue forms an amide bond with a carboxyl group of thelipophilic substituent.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer whichis an amino acid residue except Cys, or is a dipeptide such as G|y—l_ys and wherein an aminogroup of the parent peptide forms an amide bond with a carboxylic group of the amino acidresidue or dipeptide spacer, and an amino group of the amino acid residue or dipeptidespacer forms an amide bond with a carboxyl group of the lipophilic substituent.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer whichis an amino acid residue except Cys, or is a dipeptide such as Gly-Lys and wherein acarboxyl group of the parent peptide forms an amide bond with an amino group of the aminoacid residue spacer or dipeptide spacer, and the carboxyl group of the amino acid residuespacer or dipeptide spacer forms an amide bond with an amino group of the lipophilicsubstituent.in a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein a lipophilic substituent is attached to the parent peptide by means of a spacer whichis an amino acid residue except Cys, or is a dipeptide such as Gly-Lys, and wherein acarboxyl group of the parent peptide forms an amide bond with an amino group of a spacerwhich is Asp or Glu, or a dipeptide spacer containing an Asp or Glu residue, and a carboxyl1015202530CA 02264243 1999-02-25W0 98/0887] PCT/DK97/0034015group of the spacer forms an amide bond with an amino group of the lipophilic substituent.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which comprises a partially or completely hydrogenatedcyclopentanophenathrene skeleton.ln a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a straight-chain or branched alkyl group.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is the acyl group of a straight-chain or branched fatty acid.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is an acyl group selected from the group comprisingCH3(CH2),,CO-, wherein n is an integer from 4 to 38, preferably an integer from 4 to 24, morepreferred selected from the group comprising CH3(CH2),.,CO-, CH3(CH2)8CO—, CH3(CH2),,,CO-,CH3(CH2),2CO-. CH3(CH2),.,CO-, CH3(CH2),6CO-, CH3(CH2),,,CO-, CH3(CH2)2oCO-CH3(CH2)22CO-.andIn a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is an acyl group of a straight-chain or branched alkane (1.0)-dicarboxylic acid.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is an acyl group selected from the group comprisingHOOC(CH2),,,CO-, wherein m is an integer from 4 to 38, preferably an integer from 4 to 24.more preferred selected from the group comprising HOOC(CH2),4CO—, HOOC(CH2),6CO-,HOOC(CH2),,,CO-, HOOC(CH2)2oCO— and HOOC(CH2)22CO-.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a group of the formula CH3(CH2),,((CH2)qCOOH)CHNH-CO(CH2)2CO-, wherein p and q are integers and p+q is an integer of from 8 to 33, preferablyfrom 12 to 28. V‘IO15A202530CA 02264243 1999-02-25WO 98/08871 PCTIDK97/0034016In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinggroup of the CH3(CH2),CO-NHCH(COOH)(CH2)2CO-, wherein r is an integer of from 10 to 24.a lipophilic substituent which is a formulaIn a further preferred embodiment, the present invention relates to a GLP-1 derivative havinggroup of the formula CH3(CH2)sCO-NHCH((CH2)2COOH)CO-, wherein s is an integer of from 8 to 24.a lipophilic substituent which is aIn a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a group of the formula COOH(CH2),CO- wherein t is aninteger of from 8 to 24.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a group of the formula -NHCH(COOH)(CH2),,NH-CO(CH2),,CH3, wherein u is an integer of from 8 to 18.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a group of the formula -NHCH(COOH)(CH2)4NH-COCH((CH2)2COOH)NH-CO(CH2)wCH3, wherein w is an integer of from 10 to 16.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophiiic substituent which is a group of the formula —NHCH(COOH)(Cl-l2)4NH-CO(CH2)2CH(COOH)NH-CO(CH2),CH3, wherein x is an integer of from 10 to 16.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which is a group of the formula -NHCH(COOl~l)(CH2)4NH-CO(CH2)2CH(COOH)NHCO(CH2)yCH3, wherein y is zero or an integer of from 1 to 22.In a further preferred embodiment, the present invention relates to a GLP-1 derivative havinga lipophilic substituent which can be negatively charged. Such a lipophilic substituent can forexample be a substituent which has a carboxyl group.In a further preferred embodiment, the present invention relates to a GLP-1 derivative theparent peptide of which is selected from the group comprising GLP-1(1—45) or an analogue51O1U12O2530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034017thereof.In a further preferred embodiment, the present invention relates to a GLP-1 derivativederived from a GLP-1 fragment selected from the group comprising GLP-1(7-35), GLP-1(7-36), GLP—1(7-36)amide, GLP-1(7-37), GLP-t(7-38), GLP-1(7-39), GLP-1(7-40) and GLP-1(7-41) or an analogue thereof.In a further preferred embodiment, the present invention relates to a GLP-1 analogue derivedfrom a GLP-1 analogue selected from the group comprising GLP-1(1-35), GLP-1(1—36),GLP-1(1-36)amide, GLP-1(1-37), GLP-1(1-38), GLP-1(1—39), GLP-1(1-40) and GLP-1(‘l-41)or an analogue thereof.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the designation analogue comprises derivatives wherein a total of up to fifteen,preferably up to ten amino acid residues have been exchanged with any or-amino acidresidue.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the designation analogue comprises derivatives wherein a total of up to fifteen,preferably up to ten amino acid residues have been exchanged with any on-amino acidresidue which can be coded for by the genetic code.In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the designation analogue comprises derivatives wherein a total of up to six aminoacid residues have been exchanged with another on-amino acid residue which can be codedfor by the genetic code.in a further preferred embodiment, the present invention relates to a GLP—‘l(A-B) derivativewherein A is an integer from 1 to 7 and B is an integer from 38 to 45 or an analogue thereofcomprising one lipophilic substituent attached to the C-terminal amino acid residue and,optionally, a second lipophilic substituent attached to one of the other amino acid residues.In a further preferred embodiment, a parent peptide for a derivative according to theinvention is selected from the group comprising Argzs-GLP-1(7-37); Arg°“—GLP-1 (7-37); Lys°5- 1015202530CA 02264243 1999-02-25wo 98/08871 PCT/DK97/0034018GLP-1(7-37); Arg2“"“‘Lys3“’-GLP-1(7-37); Arg”-"““Lys3"GLP-1(7-38); Argzs-3‘Lys39-GLP-1(7-39);Arg2°'3‘Lys‘°-GLP-1(7-40); Arg25Lys35-GLP-1(7-37); Arg3“Lys35-GLP-1(7-37); Arg"’Lys39-GLP-1(7-39); Arg"“Lys“°-GLP-1(7-40); Arg25'3‘Lys3°'39-GLP-1(7-39); Arg2"'3"Lys3‘5"‘°-GLP-1(7-40);Giy”Arg26-GLP-1(7-37); G|y"Arg3“-GLP-1(7-37); G1y‘Lys“5-GLP-1(7-37); G|y“Arg2°"“Lys36-GLP-1(7-37); Gly“Arg26'3‘Lys39-GLP-1(7-39); Gly"Arg25-"“Lys“°-GLP-1(7-40); GIy°Arg25Lys3“-GLP-1(7-37); G1y“Arg3“Lys““-GLP-‘I(7-37); GIy*’Arg25Lys39-GLP-1(7-39); G1y“Arg““Lys“°-GLP-1(7-40); Gly“Arg2“'3‘Lys3"'“9-GLP-1 (7-39) and G|y"Arg2“"3“Lys“‘5~“°-GLP-1 (7-40).In a further preferred embodiment, a parent peptide for a derivative according to theinvention is selected from the group comprising Arg2“'3“Lys3"GLP-1(7-38); Arg2°-3‘Lys“9GLP-1(7-39); Arg2‘""3“Lys“°GLP-1(7-40); Arg2““Lys“‘GLP-1 (7-41); Arg25'3‘Lys‘2GLP-1 (7-42);Arg2“'°“‘Lys“°GLP-1 (7-43);Argzs-3‘Lys“°GLP-1 (1-38);Argze-3‘Lys“GLP-1 (1-41);Arg25~3‘Lys“GLP-1 (1-44);Argze-3‘Lys39G LP-1 (2-39);Arg2°'3‘Lys“2GLP—1 (2-42);Argze-3“Lys“5GLP-1 (2-45);Arg”-3“Lys“°GLP-1 (3-40);Arg25'3“Lys‘3GLP—1 (3-43);Arg2"”'3“Lys3"GLP-1 (4-38);Arg2'""3‘Lys“GLP-1(4-41);Arg25'3‘Lys“GLP-1 (4-44);Arg’5'3‘Lys39GLP-1 (5-39);Arg2'5""Lys“GLP-1 (5-42);Arg2°'3‘Lys‘5GLP-1 (5-45);Argzs-°“Lys“°GLP-1 (6-40);Arg2"3'3“Lys““GLF’-1 (7-44);Arg2°'3‘Lys39GLP-1(1-39);Arg2‘"’-3“Lys‘2GLP-1(1—42);Arg’5'3‘Lys‘5GLP-1 (1-45);Arg2‘5'3“Lys“°GLP-1 (2-40);Arg2°'3‘Lys‘°GLP-1 (2-43);Arg25'3‘Lys3°GLP-1 (3-38);Arg26'3“Lys‘“GLP-1 (3-41 );Arg26'“Lys‘“G LP-1 (3-44);Arg2°'3“Lys3°GLP-1 (4-39);Arg2°°“Lys‘2G LP-1 (4-42);Arg2“‘3‘Lys‘5GLP-1 (4-45);Arg2°'3‘Lys“°GLP-1 (5-40);Arg25""‘Lys“‘*GLP-1 (5-43);Argzs-3‘Lys3"GLP-1 (6-38);Arg2”‘Lys“GLP-1 (6-41 );Arg25'3‘Lys‘5GLP-1 (7-45);Arg2°-3‘Lys‘°GLP-1 (1-40);Arg2“'3‘Lys“GLP-1 (1-43);Arg2“'3“Lys3“GLP-1 (2-38);Arg2°'3‘Lys" GLP-1 (2-41 );Arg2‘"’-"“Lys““GLP-1 (2-44);Arg2°-3‘Lys39GLP-1 (3-39);Arg2°‘“Lys‘2GLP-1 (342);Arg26'“Lys‘5GLP-1 (3-45);Arg25'3“Lys‘°GLP-1 (4-40);Arg25""‘Lys‘”GLP-1 (4-43);Arg”-3‘Lys3"GLP-1 (5-38);Argzs-““Lys‘“GLP-1 (5-41);Arg2“'“Lys“G LP-1 (5-44);Arg"’°-3‘Lys‘“’GLP-1 (6-39);Arg"""3“Lys“2GLP-1 (6-42);Arg25"“Lys““GLP-1(6-43); Argzs-3“Lys““GLP-1(6-44); Arg2°'3‘Lys‘5GLP-1(6-45); Arg2°Lys“GLP-1(1-38);Arg“ Lys3"GLP-1 (1-38);Arg2”“Lys3°'3“GLP-1 (1-38);Arg2“Lys‘°“GLP-1 (7-38);Arg3“Lys3“GLP-1(7-38); Arg2°-3“Lys3°'3°GLP-1(7-38); Arg2°'“Lys33GLP-1(7-38); Arg25Lys39GLP-1(1-39);Arg3“Lys39GLP-1(1-39);Arg3“Lys39GLP-1 (7-39) and Arg26'“Lys35-3°GLP-1(7-39).Arg"-5'3‘Lys3*“’-3"GLP-1 (1-39);Arg25Lys39GLP-1 (7-39);in a further preferred embodiment. the present invention relates to a GLP-1 derivative1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034019wherein the parent peptide is selected from the group comprising Argzs-GLP-1(7-37), Arg“-GLP-1(7-37), Lys”-GLP-1(7-37), Arg2““Lys““-GLP-1(7-37), Arg'25Lys”“-GLP-1(7-37),Arg°‘Lys35-GLP-1(7-37), Gly°Arg25-GLP-1(7-37). Giy“Arg3“-GLP-1(7-37), Gly“Lys“°-GLP-1(7-37), G|y“Arg2°'3‘Lys3‘5-GLP-1(7-37), Gly"Arg25Lys3“-GLP-1(7-37) and G|y“Arg3“Lys"“-GLP-1(7-37).in a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the parent peptide is selected from the group comprising Arg2°Lys3”-GLP—1(7-38),Arg2"'3“Lys3°-GLP-1 (7-38), Arg"""3‘Lys3”"-GLP-1(7-38), G|y°Arg25Lys‘“’-GLP-1 (7-38)Gly“Arg2”‘Lys35'3°-GLP-1 (7-38).andIn a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the parent peptide is selected from the group comprising Arg26Lys39-GLP-1(7-39),Arg2°‘3“Lys35'39-GLP-1 (7-39), Gly“Arg"*"’Lys3"-GLP-1 (7-39) and G|y“Arg26-3‘Lys35-39-GLP-1 (7-39).In a further preferred embodiment, the present invention relates to a GLP-1 derivativewherein the parent peptide is selected from the group comprising Arg3“Lys“°—GLP-1(7-40),Arg25'3‘Lys36"°-GLP-1 (7-40), G|y“Arg3“Lys“°-GLP-1 (7-40) and Gly°Arg25-3‘Lys35-‘°-GLP-1(7-40).In a further preferred embodiment, the present invention relates to a GLP-1 derivative whichis selected from the group comprising:Lys’5(N‘-tetradecanoyl)-GLP-1(7-37);Lys°“(N‘-tetradecanoyl)-GLP-1 (7-37);Lys2°-3‘-bis(N‘-tetradecanoyl)-GLP-1 (7-37);Gly°Lys2‘5(N‘-tetradecanoyl)-G LP-1 (7-37);Gly“Lys3‘(N‘-tetradecanoyl)-GLP-1(7-37);Gly”Lys2”‘-bis(N‘-tetradecanoyl)-G LP-1 (7-37);Arg26Lys3“(N‘-tetradecanoy|)-GLP-1 (7-37);Lys’°(N‘-tetradecanoyl)-GLP-1 (7-38);Lys“(N‘-tetradecanoyl)-G LP-1 (7-38);Lys“-3‘-bis(N‘-tetradecanoyl)-GLP-1(7-38);Gly“Lys25(N‘-tetradecanoyl)-GLP-1 (7-38);Gly"Lys3“(N‘-tetradecanoyl)-GLP-1(7-38);1015202530CA 02264243 1999-02-25WO 98/0887120Gly“Lysze-3‘-bis(N‘-tetradecanoyl)-G LP-1 (7-38);Arg25Lys“(Nfitetradecanoyl)-GLP-1(7-38);Lys25(N‘-tetradecanoyl)-GLP-1(7-39);Lys3“(N‘-tetradecanoyl)-GLP-1(7-39);Lysm‘-bis(N‘-tetradecanoyl)-G LP-1 (7-39);Gly°Lys26(Nfitetradecanoyl)-GLP-1(7-39);Gly5Lys3“(N‘-tetradecanoyl)—GLP—1 (7-39);Gly"Lysm‘-bis(N‘-tetradecanoyi)-GLP—1(7-39);Arg25Lys3‘(N‘-tetradecanoyl)-GLP-1(7-39);Lys26(N‘-tetradecanoyl)-GLP-1(7-40);Lys““(N‘-tetradecanoyl)-GLP-1(7-40);Lysm“-bis(N‘-tetradecanoyl)-GLP-1 (7-40);Gly°Lys25(N‘-tetradecanoyl)—GLP-1(7-40);Gly“Lys3“(N‘-tetradecanoyl)-GLP-1(7-40);Gly“Lys2“"“‘-bis(N‘-tetradecanoyl)-G LP-1 (7-40);Arg26Lys3‘(N‘-tetradecanoyl)—GLP-1(7-40);Lys2"(N‘-tetradecanoy|)-GLP-1(7-36);Lys3“(N‘-tetradecanoy!)-GLP-1(7-36);Lys26'3“-bis(N‘-tetradecanoyl)-GLP-1(7-36);Gly“Lys25(N‘-tetradecanoyl)-GLP—1 (7-36);GIy"Lys3“(N‘-tetradecanoyl)-GLP—1(7-36);Gly“Lyszs“-bis(N°-tetradecanoyl)-GLP-1(7-36);Arg“Lys“(N‘-tetradecanoy|)-GLP-1(7-36);Lys25(N‘-tetradecanoyl)-GLP-1 (7-35);Lys3“(N‘-tetradecanoyl)-GLP-1 (7-35);Lys25'3‘—bis(N‘-tetradecanoy!)-GLP-1(7-35);GlyeLys25(N‘-tetradecanoyl)—GLP—1(7-35);G|y°Lys3“(N‘-tetradecanoy|)—G LP-1 (7-35);Gly‘*Lys2°"°“-bis(N‘-tetradecanoyl)-GLP-1 (7-35);Arg2“Lys3‘(N‘-tetradecanoyI)—GLP-1 (7-35);Lys2°(N‘-tetradecanoy|)-GLP-1(7-36)amide;Lys3“(N‘-tetradecanoyl)-GLP-1(7-36)amide;Lys"'""3“-bis(N‘—tetradecanoyl)—GLP-1(7-36)amide;PCT/DK97/003401015202530CAW0 98/0887121Gly°Lys25(N°-tetradecanoyl)-GLP-1(7-36)amide;Gly3Lys3"(N‘-tetradecanoyl)-GLP-1(7-36)amide;Gly“Lys2‘5'3‘-bis(N‘-tetradecanoyl)-GLP-1(7-36)amide;Arg25Lys““(N‘-tetradecanoyl)-GLP-1(7-36)amide;G|y“Arg26Lys3“(N‘-tetradecanoyl)-G LP-1 (7-37);Lys2°(N‘-tetradecanoyl)Arg3“-GLP-1 (7-37);Gly°Lys2‘°‘(N‘-tetradecanoyl)Arg3“-GLP-1 (7-37);Arg2°'°“Lys36(N‘-tetradecanoyl)-GLP-1(7-37);Gly°Arg25'°‘Lys35(N‘-tetradecanoyl)-GLP-1 (7-37);Gly“Arg2°Lys3“(N"-tetradecanoyl)-G LP-1 (7-38);Lys25(N‘-tetradecanoyl)Arg3“-G LP-1 (7-38);GlyeLys25(N‘-tetradecanoy|)Arg3“-GLP-1(7-38);Argzw Lys°“(N‘-tetradecanoyl)-G LP-1 (7-38);Arg26'3‘Lys3°(N‘-tetradecanoyl)-GLP—1(7-38);Gly°Arg2°~3‘Lys°“(N‘-tetradecanoy|)-GLP-1 (7-38);Gly5Arg26Lys3“(N‘-tetradecanoyl)-GLP-1 (7-39);Lys25(N‘-tetradecanoy|)Arg3‘-GLP-1(7-39);G|y“Lys25(N‘-tetradecanoy|)Arg3“-G LP-1 (7-39);Arg25'3"Lys35(N‘-tetradecanoyl)-GLP-1 (7-39);GIy"Arg2°'3‘Lys3“(N‘-tetradecanoyl)-GLP-1(7-39);Gly°Arg25Lys”(N‘-tetradecanoyl)-GLP-1 (7-40);Lys2“(N‘-tetradecanoy|)Arg°“-GLP-1 (7-40);Gly°Lys25(N‘-tetradecanoyl)Arg““-GLP-1 (7-40);Arg2°-3‘Lys3“(N‘-tetradecanoyl)-GLP-1 (7-40);GIy“Arg2"““Lys3"(N‘-tetradecanoyl)-GLP-1 (7-40);Lys2°(N‘-(ca-carboxynonadecanoyI))-GLP—1(7-37);Lys“(N‘-(an-carboxynonadecanoyl))-GLP-1(7-37);Lys25'3‘—bis(N‘-(co-carboxynonadecanoyl))—GLP-1 (7-37);Gly“Lys26(N‘-(co-carboxynonadecanoy|))-GLP-1 (7-37);Gly°Lys°‘(N‘-(co-carboxynonadecanoy|))-GLP-1(7-37);G|y*’Lys25'3‘-bis(N‘-(m—carboxynonadecanoyl))-GLP-1 (7-37);Lys2“(N‘-(m-carboxynonadecanoyl))-GLP-1(7-38);Lys3‘(N‘-(co-carboxynonadecanoyl))-GLP-1(7-38);02264243 1999-02-25PCTIDK97/003401015202530CA 02264243 1999-02-25WO 98/0887122Lys2°'“-bis(N‘-(cu-carboxynonadecanoyI))-GLP-1 (7-38);GIy“Lys26(N‘-(m-carboxynonadecanoyl))-GLP-1(7-38);Gly8Lys3“(N‘-(tn-carboxynonadecanoyl))-GLP-1(7-38);Gly"Lys2°'3‘-bis(N‘-(m-carboxynonadecanoyl))-GLP—1(7-38);Lys‘°-‘"’(N‘-(co-carboxynonadecanoyl))-G LP-1 (7-39);Lys3“(N‘-(co-carboxynonadecanoy|))-GLP-1 (7-39);Lyszs-3‘-bis(N‘-(cu-carboxynonadecanoyl))-GLP-1(7-39);Gly“Lys25(N‘-(co-carboxynonadecanoyl))-GLP-1(7-39);G|y“Lys3“(N‘-(co-carboxynonadecanoy|))-GLP-1(7-39);Gly"Lys25'3“-bis(N‘-(co-carboxynonadecanoy|))-GLP-1(7-39);Lys2“(N‘-(co-carboxynonadecanoyl))-GLP-1(7-40);Lys°“(N‘-(m-carboxynonadecanoyl))-GLP-1(7-40);Lys2““-bis(N‘-(co-carboxynonadecanoyI))-GLP-1 (7-40);Gly”Lys25(N‘-(a)-carboxynonadecanoyl))-GLP-1 (7-40);Gly“Lys3“(N‘-(co-carboxynonadecanoyl))-GLP-1(7-40);Gly“Lys2‘5'3“—bis(N‘-(m-carboxynonadecanoyl))-GLP-1 (7-40);Lys2°(N‘-(on-carboxynonadecanoyl))-GLP-1(7-36);Lys3“(N‘-(co-carboxynonadecanoyl))-G LP-1 (7-36);Lys2°'3“-bis(N‘-(ca-carboxynonadecanoyI))-GLP-1 (7-36);Gly“Lys2‘5(N‘-(co-carboxynonadecanoyl))-GLP-1(7-36);Gly3Lys““(N‘-(on-carboxynonadecanoy|))-GLP-1(7-36);Gly°Lys2°‘3‘-bis(N‘-(co-carboxynonadecanoyl))-G LP-1 (7-36);Lys2“(N°-(ca-carboxynonadecanoyl))-GLP-1(7-36)amide;Lys“(N‘-(cu-carboxynonadecanoyl))-GLP-1(7-36)amide;Lysm“-bis(N‘-(m-carboxynonadecanoyl))-GLP-1(7-36)amide;Gly“Lys25(N‘-(co-carboxynonadecanoyl))-GLP-1(7-36)amide;GIy“Lys3“(N‘-(co-carboxynonadecanoy|))-GLP-1(7-36)amide;Gly“Lys2°'3“-bis(N‘-(oo-carboxynonadecanoyl))-GLP-1(7-36)amide;Lys25(N‘-(co-carboxynonadecanoy|))-GLP-1 (7-35);Lys3“(N‘-(w—carboxynonadecanoyl))-GLP-‘I (7-35);Lysm‘-bis(N‘-(u>—carboxynonadecanoyl))-G LP-1 (7-35);GlyeLys26(N‘-(co—carboxynonadecanoyl))-GLP-1(7-35);Gly"Lys3“(N‘-(m—c:arboxynonadecanoyl))-GLP-1(7-35);PCT/DK97/003401015202530CA 02264243 1999-02-25WO 98/0887]23Gly°Lys2“'3‘-bis(N‘-(cn—carboxynonadecanoy|))-G LP-1 (7-35);ArgzeLys“(N‘-(awcarboxynonadecanoyl))-G LP-1 (7-37);GIy“Arg25Lys3“(N‘-(as-carboxynonadecanoyl))-GLP-1 (7-37);Lys2°(N‘-(a>—carboxynonadecanoy|))Arg3“-GLP-1 (7-37);Gly”Lys2"(N‘—(o)—carboxynonadecanoyl))Arg3“-GLP-1 (7-37);Arg2“'3‘Lys3‘"’(N‘-(co—carboxynonadecanoy|))-GLP-1 (7-37);G|y“Arg2°'3“Lys3"(N‘—(u)—carboxynonadecanoy|))-GLP-1 (7-37);Arg"-5Lys3‘(N‘-(m—carboxynonadecanoy|))-G LP-1 (7-38);Gly°Arg2“Lys3“(N‘-(o)—carboxynonadecanoyI))-GLP-1 (7-38);Lys2“(N‘-(co-carboxynonadecanoy|))Arg3“-GLP-1(7-38);Gly”Lys25(N‘-(m-carboxynonadecanoyl))Arg3“-GLP-1(7-38);Arg25'3‘Lys35(N‘-(w—carboxynonadecanoy|))-GLP-1(7-38);Argzs“Lys°‘(N‘-(cn—carboxynonadecanoy|))-G LP-1 (7-38);G|y‘Arg25-3‘Lys3“(N‘-(<n—carboxynonadecanoyl))-GLP-1 (7-38);ArgzeLys3“(N‘-(m—carboxynonadecanoy|))-GLP-1 (7-39);Gly"Arg2°Lys3“(N‘-(urcarboxynonadecanoyl))-GLP-1 (7-39);Lys2°(N‘-(co—carboxynonadecanoyl))Arg3“-GLP—1 (7-39);Gly"Lys"'°(N‘-(co—carboxynonadecanoy|))Arg3“-G LP-1 (7-39);Arg2°'°“Lys3“(N‘-(oa—carboxynonadecanoyl))-GLP-1 (7-39);G|y"Arg2”“Lys"5(N‘-(orcarboxynonadecanoyl))-GLP-1(7-39);Arg2"Lys3‘(N‘-(m—carboxynonadecanoy|))-GLP-1 (7-40);Gly"Arg2°Lys3“(N‘-(co—carboxynonadecanoy|))-GLP-1(7-40);Lys26(N‘-(m—carboxynonadecanoyl))Arg3“-GLP-1(7-40);G|y"Lys25(N‘-(oo—carboxynonadecanoyl))Arg““-G LP-1 (7-40);Argza-3‘Lys35(N°-(w—carboxynonadecanoyl))-GLP-1 (7-40);GIy°Arg25-3‘Lys35(N‘-(oa—carboxynonadecanoyl))-GLP-1(7-40);Lys2“(N‘-(7-deoxycho|oy|))-G LP-1 (7-37);Lys3“(N‘-(7-deoxychoIoyl))-G LP-1 (7-37);Lys2°'3‘-bis(N‘-(7-deoxycholoyl))-GLP-1(7-37);Gly‘Lys25(N‘-(7-deoxycholoyl))-GLP-1(7-37);G|y°Lys“(N‘-(7-deoxycho|oyl))-GLP-1 (7-37);Gly”Lysm“-bis(N‘-(7-deoxycholoyl))-GLP-1 (7-37);Arg26Lys°‘(N‘-(7-deoxycholoyl))-GLP-1 (7-37);PCT/DK97l003401015202530CA 02264243 1999-02-25WO 98/0887]24Lys"'5(N‘-(7-deoxycho|oy|))-GLP-1(7-38);Lys3“(N‘-(7-deoxycholoyl))-GLP-1(7-38);Lys2°-'°"‘-bis(N‘-(7-deoxychoIoyl))-GLP-1 (7-38);Gly°Lys26(N‘-(7-deoxychoIoyl))-GLP-1(7-38);G)y“Lys3“(N‘-(7-deoxycholoy|))-GLP-1(7-38);G|y“Lys2°'3“-bis(N“-(7-deoxycholoyl))-G LP-1 (7-38);ArgzfiLys°"(N‘-(7-deoxychoIoyl))-GLP-1(7-38);Lys25(N‘-(7-deoxycholoyl))-GLP-1(7-39);Lys3"(N‘-(7-deoxycho|oyl))-GLP-1 (7-39);Lys2““-bis(N‘-(7-deoxycholoyl))-GLP-1 (7-39);GIy°Lys25(N‘-(7-deoxycholoyl))-GLP-1 (7-39);G|y"Lys3“(N‘-(7-deoxychoIoyI))-GLP-1 (7-39);GIy°Lys2°~3‘-bis(N‘-(7-deoxycho1oy|))-G LP-1 (7-39);ArgzsLys3"(N‘-(7-deoxycholoyl))-G LP-1 (7-39);Lys2°(N‘-(7-deoxycho|oyl))-G LP-1 (7-40);Lys3“(N‘-(7-deoxycholoyl))-GLP-1(7-40);Lyszw-bis(N‘-(7-deoxycholoyl))-GLP-1(7-40);G|y°Lys2‘5(N‘-(7-deoxycholoyl))-GLP-1(7-40);Gly“Lys3“(N‘-(7-deoxycholoyl))-GLP-1(7-40);G!y"Lys2“"‘-bis(N‘-(7-deoxycholoyl))-GLP—1 (7-40);Arg25Lys3“(N‘-(7—deoxycholoy|))-GLP-1(7-40);Lys"’5(N‘-(7-deoxycho|oy|))-GLP—1 (7-36);Lys3“(N‘-(7-deoxycholoyl))-GLP-1 (7-36);Lys25'3‘-bis(N‘—(7-deoxycholoyl))-GLP-1(7-36);Gly“Lys2“(N‘-(7-deoxycholoyl))-GLP-1 (7-36);Gly"Lys3“(N‘-(7-deoxycholoyl))-GLP-1 (7-36);Gly”Lys2“‘—bis(N‘-(7-deoxycholoyl))-GLP—1 (7-36);ArgzsLys3“(N‘-(7-deoxycholoyl))-GLP-1(7-36);Lys2"(N‘-(7-deoxycholoyl))-GLP~1 (7-35);Lys3“(N‘-(7-deoxycholoyl))-GLP-1 (7-35);Lys2°-3‘-bis(N‘-(7-deoxycholoyl))-GLP-1(7-35);Gly”Lys25(N‘-(7-deoxycholoyl))-GLP-1(7-35);Gly“Lys3“(N‘-(7-deoxycholoyl))-GLP-1 (7-35);PCT/DK97/003401015202530CA 02264243 1999-02-25W0 98/0887125GlyaLyszw-bis(N‘-(7-deoxycholoyl))-G LP-1 (7-35);Arg26Lys°“(N‘-(7-deoxycholoy|))—GLP-1 (7-35);Lys2°(N‘-(7-deoxycholoyl))-GLP-1(7-36)amide;Lys“(N‘-(7-deoxycho!oy|))-GLP-1(7-36)amide;Lysm‘-bis(N‘-(7-deoxycholoy|))-G LP-1 (7-36)amide;Gly“Lys2°(N‘-(7-deoxycholoyl))-GLP-1(7-36)amide;Gly"Lys3“(N‘-(7-deoxycholoyl))-GLP-1(7—36)amide;Gly“Lyszw-bis(N‘-(7-deoxycholoyl))-GLP—1(7-36)amide;Arg25Lys3‘(N‘-(7-deoxycholoyl))-GLP-1(7-36)amide;Gly"Arg25Lys3“(N‘-(7-deoxycholoyI))-GLP-1(7-37);Lys25(N‘-(7-deoxycho|oyl))Arg3“-G LP-1 (7-37);GlyaLys25(N‘-(7—deoxycho|oy|))Arg3“-GLP-1(7-37);Argzs“ Lys35(N‘-(7-deoxycholoyl))—G LP-1 (7-37);Gly“Arg2‘5-3‘Lys35(N‘-(7-deoxycholoy|))—G LP-1 (7-37);Lys26(N°-(choloyl))-GLP-1(7-37);Lys3“(N‘-(choloy|))-GLP-1(7-37);Lys25'3“-bis(N‘—(choloy|))-GLP—1 (7-37);G|y°Lys2"(N‘-(choloyl))—GLP-1(7-37);GlyeLys3"(N°-(choloyl))—GLP-1(7-37);Gly°Lys2°'3“-bis(N°—(cho|oy|))-GLP-1(7-37);Arg25Lys3“(N‘-(choloyl))—G LP-1 (7-37);Gly"Arg26Lys3“(N‘-(7—deoxychoIoyl))-GLP-1(7-38);Lys25(N‘—(7-deoxycho|oyl))Arg3“-G LP-1 (7-38);Gly“Lys2°(N‘-(7-deoxycholoyl))Arg3“-G LP-1 (7-38);Arg26‘3‘Lys3°(N‘-(7-deoxycho|oyl))-GLP-1(7-38);Argzs-3“Lys°‘(N°-(7-deoxycholoy|))-GLP-1 (7-38);Gly°Arg’6'3‘Lys°“(N‘—(7—deoxycholoyl))-G LP-1 (7-38);Lys2°(N‘-(cho|oy|))—GLP-1(7-38);Lys“(N‘-(choloyI))-GLP-1(7-38);Lys26'°‘-bis(N‘-(choloyl))-GLP-1(7-38);Gly"Lys26(N‘-(choloyI))-GLP—1(7-38);G|y"Lys"“(N‘-(choloy|))—GLP~1(7-38);Gly°Lys26'“—bis(N‘—(choIoyl))-GLP-1 (7-38);PCT/DK97/003401015202530CA 02264243 1999-02-25WO 98/0887126Arg25Lys3“(N‘-(choloyl))-GLP-1 (7-38);Gly“Arg‘°'6Lys3‘(N‘-(7-deoxycholoyl))-GLP—1 (7-39);Lys25(N‘-(7-deoxycholoyl))Arg3“-GLP-1(7-39);GIy”Lys25(N‘-(7-deoxycholoyI))Arg3“—GLP-‘I (7-39);Arg2“'3‘Lys°5( N‘-(7—deoxychoIoy|))-G LP-1 (7-39);GIy"Arg26'°‘Lys35(N‘-(7-deoxycholoy|))-G LP-1 (7-39);Lys2“(N‘-(choloyl))—GLP-1(7-39);Lys3“(N‘—(choloyl))-GLP-1(7-39);Lys25'3“-bis(N‘-(choioyl))—GLP-1 (7-39);Gly"Lys26(N‘—(cho|oyl))-GLP-1(7-39);Gly5Lys3“(N‘—(choloyl))-GLP-1(7-39);Gly“Lysm‘-bis(N‘-(choloyl))-GLP-1 (7-39);Arg2"Lys"“(N‘-(choloyl))-GLP-1(7-39);Gly“Arg25Lys3"(N‘-(7-deoxycholoyl))-GLP-1(740);Lys2‘5(N‘-(7-deoxycholoyl))Arg3“—GLP-1 (7-40);Gly°Lys”6(N‘-(7-deoxycholoyl))Arg3“—GLP-1 (7-40);Arg25'3‘Lys36(N‘-(7-deoxycholoyl))—GLP—1 (7-40);GIy“Arg25'3“Lys3"(N‘-(7-deoxycholoyl))-GLP-1(7-40);Lys2"(N‘-(choloyl))-GLP-1(7-40);Lys3“(N‘-(choloy|))-GLP-1(7-40);Lyszs“-bis(N‘—(cho|oyl))—GLP-1 (7-40);GIy“Lys2°(N‘-(choloy|))-GLP-1(7-40);Gly“Lys"“(N‘-(c:holoyl))-GLP-1(7-40);Gly“Lys25'3‘-bis(N‘-(choloyI))-GLP-1(7-40);Arg26Lys3“(N‘-(choloyl))-GLP-1(7-40);Lys2‘"’(N‘-(choloyl))-GLP-1 (7-36);Lys°“(N‘-(choloyl))-G LP-1 (7-36);Lys2°'3‘-bis(N‘-(cho|oyI))-GLP-1 (7-36);Gly°Lys2°(N‘-(choloy|))-GLP-1 (7-36);G|y“Lys3“(N‘-(choloyl))-GLP—1 (7-36);G|y"Lys2‘5'3“—bis(N‘-(choloyl))-GLP-1 (7-36);Arg25Lys3“(N‘-(choloyl))—GLP-1 (7-36);Lys25(N‘-(choloyi))-GLP-1 (7-35);PCT/DK97/003401015202530CA 02264243 1999-02-25W0 98/0887127Lys3“(N‘-(choloy|))-GLP-1 (7-35);Lys25'3“-bis(N‘-(choloy|))-GLP-1 (7-35);G|y“Lys’°(N‘-(choloyl))-G LP-1 (7-35);Gly”Lys‘“(N‘-(choloy|))-GLP-1 (7-35);Gly"Lys2'5'3‘—bis(N‘—(choIoyl))-GLP-1 (7-35);Arg25Lys3“(N‘-(cho|oyl))-GLP-1 (7-35);Lys25(N‘-(choloyl))—GLP-1(7-36)amide;Lys3“(N‘-(choloyl))-GLP—1(7-36)amide;Lys25-3‘-bis(N‘-(cho|oy|))-GLP-1(7—36)amide;G|y°Lys2"(N‘-(choIoy|))-GLP-1(7-36)amide:Gly"Lys3“(N‘-(choloy|))-GLP-1(7-36)amide;Gly°Lys25'°“-bis(N‘-(cho|oyl))—GLP-1(7-36)amide;Arg2‘5Lys°“(N‘-(choloyl))-GLP-1(7-36)amide;G|y"Arg2“Lys3“(N‘-(choloy|))-G LP-1 (7-37);Lys25(N‘—(ChOlOy|))Arg34-GLF’—1 (7-37);G|y"Lys2‘5(N‘-(choloyl))Arg3“-GLP-1(7-37);Arg25'3‘Lys35(N‘-(choloyl))—GLP-1(7-37);Gly“Arg2°'3‘Lys3“(N‘—(choloyl))-GLP—1 (7-37);Lys2°(N‘-(|ithocho|oyl))-GLP-1(7-37);Lys3“(N‘-(lithocholoyI))-GLP-1(7-37);Lys2°-3‘-bis(N‘-(lithocholoyl))-GLP-1(7-37);Gly"Lys25(N‘-(lithocho|oy|))-GLP—1(7-37);Gly3Lys3‘(N“-(Iithocholoyl))-GLP-1(7-37);Gly"Lys2"~3‘-bis(N°—(lithocholoyl))—GLP-1(7-37);Arg26Lys3“(N‘-(|ithocho|oy|))-GLP-1(7-37);G|y"Arg’°Lys°“(N‘-(cho|oy|))-GLP-1 (7-38);Lys26(N°-(choloyl))Arg3“-GLP-1(7-38);Gly°Lysze(N‘-(choloy|))Arg3‘-G LP-1 (7-38);Arg25'3‘Lys35(N‘-(choloyl))-GLP—1(7-38);Arg”-3“Lys3°(N‘-(choloyl))-GLP-1(7-38);G|y"Arg2“~3“Lys3‘5(N‘-(choloyl))-GLP-1 (7-38);Lys26(N‘-(lithocholoyl))-GLP-1(7-38);Lys3‘(N‘-(|ithochoIoyl))-GLP-1(7-38);PCT/DK97/003401015202530CA 02264243 1999-02-25W0 98/0887128Lys25'3“-bis(N‘-(|ithocho|oy|))-GLP-1(7-38);G|y"Lys2°(N‘—(lithocholoy|))-GLP-1 (7-38);Gly°Lys3“(N°-(lithocholoyl))-GLP-1(7-38);G|y°Lys"""°‘-bis(N‘-(lithocho|oyl))-GLP-1 (7-38);Arg25Lys“(N‘-(Iithocholoyl))-GLP-1(7-38);Gly“Arg25Lys°“(N‘-(choloyl))-GLP-1(7-39);Lys25(N‘-(ChO|0y|))Arg3‘-G LP-1 (7-39);Gly“Lys25(N‘-(choloy|))Arg3“-GLP-1(7-39);Arg25'3“Lys35(N‘-(cho|oy|))-GLP-1(7-39);Gly“Arg25'“Lys35(N‘-(cho|oyl))-GLP-1(7-39);Lys26(N‘-(lithocholoyl))-GLP—1(7-39);Lys3“(N‘-(lithocholoyl))-GLP-1 (7-39);Lysze“-bis(N‘-(lithocho|oy|))-GLP-1(7-39);GlyaLys2“(N”-(lithocholoy|))-GLP-1(7-39);GIyaLys“(N‘-(|ithocho|oyI))-GLP-1(7-39);G|y°Lys25'3‘—bis(N‘-(lithocholoyl))-GLP-1(7-39);Arg2"Lys3‘(N‘-(lithocholoyl))-GLP-1(7-39);Gly"Arg26Lys3“(N‘-(choloyl))-GLP-1 (7-40);Lys25(N‘-(choloyl))Arg3“-GLP-1 (7-40);G|y"Lys26(N‘-(choloyi))Arg3“-GLP-1(7-40);Arg25'3‘Lys35(N‘-(choloyl))—GLP-‘I (7-40);Gly"Arg2°'3“Lys35(N‘-(choIoy|))-GLP—1(7-40);Lys2'"’(N‘-(lithocholoyl))-GLP-1(7-40);Lys°"(N‘-(IithocholoyI))—GLP-1(7-40);Lys26'3‘-bis(N‘-(|ithoCh0loyI))-GLP-1(7-40);G|y"Lys26(N‘-(|ithochoIoyl))-GLP-1(7-40);Gly‘Lys3“(N‘-(Iithocholoy|))-GLP-1(7-40);Gly“Lys2"-3“—bis(N‘-(Iithocholoyl))—GLP-1 (7-40);Arg2°Lys3“(N‘-(lithocholoyl))-GLP-1 (7-37);Lys25(N‘-(lithocho|oyI))-GLP-1 (7-36);Lys3“'(N‘-(lithocholoy|))-GLP-1 (7-36);Lyszs-3‘-bis(N‘-(lithocho|oyl))-GLP—1 (7-36);Gly”Lys2‘5(N‘-(|ithochoIoy|))-GLP-1 (7-36);PCT/DK97/00340 1015202530CA 02264243 1999-02-25W0 98/0887129Gly"Lys°“(N‘-(lithochoIoyl))-GLP-1 (7-36);GlyaLys2“'3“-bis(N‘-(Iithocho|oy|))-GLP-1 (7-36);Arg25Lys““(N‘-(lithochoIoy|))-GLP-1 (7-36);Lys25(N‘-(lithocholoyl))-GLP-1 (7-35);Lys3“(N‘-(lithocho1oy|))-GLP-1(7-35);Lysm‘-bis(N‘-(lithocho!oy|))-GLP—1(7-35);Gly"Lys25(N‘-(lithocholoy|))—GLP-1(7-35);Gly"Lys3“(N°-(|ithocho|oy|))—GLP-1(7-35);GIy“Lys2°"“-bis(N‘-(lithocholoyl))-GLP-1(7-35);Arg25Lys3“(N‘-(lithochoIoy|))-GLP-1(7-35);Lys2“(N‘-(lithochoIoy|))-GLP-1(7-36)amide;Lys°“(N‘-(lithocho|oyl))-GLP-1(7-36)amide;Lys"""“-bis(N"—(lithocho|oy|))-GLP-1(7-36)amide;Gly°Lys25(N‘-(|ithochoioy|))-GLP-1(7-36)amide;Gly“Lys3“(N‘-(iithochoIoyl))-GLP-1(7-36)amide;G|y”Lys2“'3“-bis(N‘-(lithocholoyl))-GLP-1(7—36)amide;Arg25Lys3“(N‘-(|ithocholoy|))—GLP—1(7-36)amide;G|y°Arg26Lys3“(N‘-(lithocholoy|))—GLP-1 (7-37);Lys2“(N‘-(lithocholoyl))Arg3“-GLP-1(7-37);Gly"Lys25(N‘—(lithocho|oy|))Arg”“—GLP-1 (7-37);Arg26'3‘Lys3°(N‘—(Iithocho|oy|))-GLP-1 (7-37);ArgzwLys3“(N‘-(lithocholoy|))-GLP-1(7-37);G|y°Arg26'3“Lys3°(N‘-(|ithocho|oyl))-GLP-1 (7-37);GIy°Arg26Lys3“(N‘-(lithocho|oyl))-G LP-1 (7-38);Lys25(N‘-(lithocholoyl))Arg3‘-GLP-1(7-38);Gly“Lys2“(N°-(Iithocholoyl))Arg°“-GLP-1 (7-38);Arg25'3“Lys3“(N‘-(|ithocholoyl))-GLP-1(7-38);Arg2““Lys3”(N‘-(lithocholoy|))-G LP-1 (7-38);G|y“Arg2““Lys35(N‘-(IithocholoyI))-GLP—1 (7-38);GIy"Arg2°Lys3“(N‘-(lithocholoyl))-GLP-1 (7-39);Lys25(N‘-(lithocholoyl))Arg3“-GLP-1 (7-39);G|y"Lys2“(N‘-(Iithocho|oy|))Arg°“-GLP-1 (7-39);Arg26'3‘Lys3°(N‘-(Iithocholoyl))-GLP-1 (7-39);PCT/DK97/003401015202530CA 02264243 1999-02-25WO 98/08871 PCTIDK97/0034030G|y’3Arg25'3“Lys3°(N‘-(|ithocholoy|))—GLP-1 (7-39);Gly"Arg25Lys3“(N‘-(Iithocholoy|))-GLP-1(7-40);Lys25(N‘-(lithocholoyl))Arg3‘-GLP-1 (7-40);Gly“Lys2‘5(N‘-(Iithocholoy|))Arg3“-GLP-1 (7-40);Arg25'3“Lys36(N‘-(lithocholoyl))-GLP-1 (7-40) andGly“Arg25'“Lys3°(N‘-(lithocholoyI))-G LP-1 (7-40).In a further preferred embodiment, the present invention relates to a pharmaceuticalcomposition comprising a GLP—1 derivative and a pharmaceutically acceptable vehicle orcarrier.In a further preferred embodiment, the present invention relates to the use of a GLP-1derivative according to the invention for the preparation of a medicament which has aprotracted profile of action relative to GLP-1 (7-37).In a further preferred embodiment, the present invention relates to the use of a GLP-1derivative according to the invention for the preparation of a medicament with protractedeffect for the treatment of non-insulin dependent diabetes mellitus.in a further preferred embodiment, the present invention relates to the use of a GLP-1derivative according to the invention for the preparation of a medicament with protractedeffect for the treatment of insulin dependent diabetes mellitus.in a further preferred embodiment, the present invention relates to the use of a GLP-1derivative according to the invention for the preparation of a medicament with protractedeffect for the treatment of obesity.In a further preferred embodiment, the present invention relates to a method of treatinginsulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such atreatment, comprising administering to the patient a therapeutically effective amount of aGLP-1 derivative according to claim 1 together with a pharmaceutically acceptable carrier.DETAILED DESCRIPTION OF THE INVENTION1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97/0034031To obtain a satisfactory protracted profile of action of the GLP~1 derivative, the lipophilicsubstituent attached to the GLP-1 moiety preferably comprises 4-40 carbon atoms, inparticular 8-25 carbon atoms. The lipophilic substituent may be attached to an amino groupof the GLP-1 moiety by means of a carboxyl group of the lipophilic substituent which formsan amide bond with an amino group of the amino acid residue to which it is attached.Alternatively, the lipophilic substituent may be attached to said amino acid residue in such away that an amino group of the lipophilic substituent forms an amide bond with a carboxylgroup of the amino acid residue. As a further option, the lipophilic substituent may be linkedto the GLP-1 moiety via an ester bond. Formally, the ester can be formed either by reactionbetween a carboxyl group of the GLP-1 moiety and a hydroxyl group of the substituent-to-beor by reaction between a hydroxyl group of the GLP-1 moiety and a carboxyl group of thesubstituent-to-be. As a further alternative, the lipophilic substituent can be an alkyl groupwhich is introduced into a primary amino group of the GLP-1 moiety.In one preferred embodiment of the invention, the lipophilic substituent is attached to theGLP-1 moiety by means of a spacer in such a way that a carboxyl group of the spacer formsan amide bond with an amino group of the GLP-1 moiety. Examples of suitable spacers aresuccinic acid, Lys, Glu or Asp, or a dipeptide such as Gly-Lys. When the spacer is succinicacid, one carboxyl group thereof may form an amide bond with an amino group of the aminoacid residue, and the other carboxyl group thereof may form an amide bond with an aminogroup of the lipophilic substituent. When the spacer is Lys, Glu or Asp, the carboxyl groupthereof may form an amide bond with an amino group of the amino acid residue, and theamino group thereof may form an amide bond with a carboxyl group of the lipophilicsubstituent. When Lys is used as the spacer, a further spacer may in some instances beinserted between the e-amino group of Lys and the lipophilic substituent. In one preferredembodiment, such a further spacer is succinic acid which forms an amide bond with the 5-amino group of Lys and with an amino group present in the lipophilic substituent. in anotherpreferred embodiment such a further spacer is Glu or Asp which forms an amide bond withthe e-amino group of Lys and another amide bond with a carboxyl group present in thelipophilic substituent, that is, the lipophilic substituent is a N‘-acylated lysine residue.in another preferred embodiment of the present invention, the lipophilic substituent has agroup which can be negatively charged. One preferred group which can be negatively..i._.................. ....... .. ... ..,.i...i,........................_N, .1015202530CA 02264243 1999-02-25W0 98/0887] PCT/DK97/0034032charged is a carboxylic acid group.The parent peptide can be produced by a method which comprises culturing a host cellcontaining a DNA sequence encoding the polypeptide and capable of expressing thepolypeptide in a suitable nutrient medium under conditions permitting the expression of thepeptide, after which the resulting peptide is recovered from the culture.The medium used to culture the cells may be any conventional medium suitable for growingthe host cells, such as minimal or complex media containing appropriate supplements. Suit-able media are available from commercial suppliers or may be prepared according topublished recipes (e.g. in catalogues of the American Type Culture Collection). The peptideproduced by the cells may then be recovered from the culture medium by conventionalprocedures including separating the host cells from the medium by centrifugation or filtration,precipitating the proteinaceous components of the supernatant or filtrate by means of a salt,e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ionexchange chromatography, gel filtration chromatography, affinity chromatography, or the like,dependent on the type of peptide in question.The DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin,for instance obtained by preparing a genomic or cDNA library and screening for DNAsequences coding for all or part of the peptide by hybridisation using syntheticoligonucleotide probes in accordance with standard techniques (see, for example,Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the peptidemay also be prepared synthetically by established standard methods, e.g. thephosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22(1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801- 805. The DNA sequence may also be prepared by polymerase chain reaction using specificprimers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 -491.The DNA sequence may be inserted into any vector which may conveniently be subjected torecombinant DNA procedures, and the choice of vector will often depend on the host cell intowhich it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e.1015202530CA 02264243 1999-02-25WO 93103371 PCT/DK97/0034033a vector which exists as an extrachromosomal entity, the replication of which is independentof chromosomal replication, e.g. a plasmid. Alternatively, the vector maybe one which, whenintroduced into a host cell, is integrated into the host cell genome and replicated togetherwith the chromosome(s) into which it has been integrated.The vector is preferably an expression vector in which the DNA sequence encoding thepeptide is operably linked to additional segments required for transcription of the DNA, suchas a promoter. The promoter may be any DNA sequence which shows transcriptional activityin the host cell of choice and may be derived from genes encoding proteins eitherhomologous or heterologous to the host cell. Examples of suitable promoters for directing thetranscription of the DNA encoding the peptide of the invention in a variety of host cells arewell known in the art, cf. for instance Sambrook et a/., supra.The DNA sequence encoding the peptide may also, if necessary, be operably connected to asuitable terminator, polyadenylation signals, transcriptional enhancer sequences, andtranslational enhancer sequences. The recombinant vector of the invention may furthercomprise a DNA sequence enabling the vector to replicate in the host cell in question.The vector may also comprise a selectable marker, e.g. a gene the product of whichcomplements a defect in the host cell or one which confers resistance to a drug, e.g.ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.To direct a parent peptide of the present invention into the secretory pathway of the hostcells, a secretory signal sequence (also known as a leader sequence, prepro sequence orpre sequence) may be provided in the recombinant vector. The secretory signal sequence isjoined to the DNA sequence encoding the peptide in the correct reading frame. Secretorysignal sequences are commonly positioned 5' to the DNA sequence encoding the peptide.The secretory signal sequence may be that normally associated with the peptide or may befrom a gene encoding another secreted protein.The procedures used to ligate the DNA sequences coding for the present peptide, thepromoter and optionally the terminator and/or secretory signal sequence, respectively, and toinsert them into suitable vectors containing the information necessary for replication, are wellknown to persons skilled in the art (cf., for instance, Sambrook et al.., supra).1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034034The host cell into which the DNA sequence or the recombinant vector is introduced may beany cell which is capable of producing the present peptide and includes bacteria, yeast, fungiand higher eukaryotic cells. Examples of suitable host cells well known and used in the artare, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO celllines.Examples of compounds which can be useful as GLP-1 moieties according to the presentinvention are described in international Patent Application No. WO 87/06941 (The GeneralHospital Corporation) which relates to a peptide fragment which comprises GLP-1(7-37) andfunctional derivatives thereof and to its use as an insulinotropic agent.Further GLP-1 analogues are described in international Patent Application No. 90/11296(The General Hospital Corporation) which relates to peptide fragments which compriseGLP-1(7-36) and functional derivatives thereof and have an insulinotropic activity whichexceeds the insulinotropic activity of GLP-1(l-36) or GLP-1(1-37) and to their use asinsulinotropic agents.International Patent Application No. 91/1145? (Buckley et aI..) discloses analogues of theactive GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 which can also be useful as GLP-1moieties according to the present invention.Pharmaceutical compositionsPharmaceutical compositions containing a GLP-1 derivative according to the presentinvention may be administered parenterally to patients in need of such a treatment.Parenteral administration may be performed by subcutaneous, intramuscular or intravenousinjection by means of a syringe, optionally a pen—like syringe. Alternatively, parenteraladministration can be performed by means of an infusion pump. A further option is acomposition which may be a powder or a liquid for the administration of the GLP-1 derivativein the form of a nasal or pulmonal spray. As a still further option, the GLP-1 derivatives of theinvention can also be administered transdermally, eg. from a patch, optionally aiontophoretic patch, or transmucosally, e.g. bucally.1015202530CA 02264243 1999-02-25W0 98/08871 PCTIDK97/0034035Pharmaceutical compositions containing a GLP-1 derivative of the present invention may beprepared by conventional techniques, e.g. as described in Remington's PharmaceuticalSciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19"‘ edition, 1995.Thus, the injectable compositions of the GLP-1 derivative of the invention can be preparedusing the conventional techniques of the pharmaceutical industry which involves dissolvingand mixing the ingredients as appropriate to give the desired end product.According to one procedure, the GLP-1 derivative is dissolved in an amount of water which issomewhat less than the final volume of the composition to be prepared. An isotonic agent, apreservative and a buffer is added as required and the pH value of the solution is adjusted - ifnecessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxideas needed. Finally, the volume of the solution is adjusted with water to give the desiredconcentration of the ingredients.Examples of isotonic agents are sodium chloride, mannitol and glycerol.Examples of preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzylalcohol.Examples of suitable buffers are sodium acetate and sodium phosphate.Further to the above-mentioned components, solutions containing a GLP-1 derivativeaccording to the present invention may also contain a surfactant in order to improve thesolubility and/or the stability of the GLP-1 derivative.A composition for nasal administration of certain peptides may, for example, be prepared asdescribed in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785.According to one preferred embodiment of the present invention, the GLP-1 derivative isprovided in the form of a composition suitable for administration by injection. Such acomposition can either be an injectable solution ready for use or it can be an amount of asolid composition, e.g. a lyophilised product, which has to be dissolved in a solvent before it1015202530CA 02264243 1999-02-25W0 98l08871 PCT/DK97/0034036can be injected. The injectable solution preferably contains not less than about 2 mg/ml,preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of theGLP-1 derivative and, preferably, not more than about 100 mg/ml of the GLP-1 derivative.The GLP-1 derivatives of this invention can be used in the treatment of various diseases.The particular GLP-1 derivative to be used and the optimal dose level for any patient willdepend on the disease to be treated and on a variety of factors including the efficacy of thespecific peptide derivative employed, the age. body weight, physical activity, and diet of thepatient, on a possible combination with other drugs, and on the severity of the case. it isrecommended that the dosage of the GLP-1 derivative of this invention be determined foreach individual patient by those skilled in the art.in particular, it is envisaged that the GLP-1 derivative will be useful for the preparation of amedicament with a protracted profile of action for the treatment of non-insulin dependentdiabetes mellitus and/or for the treatment of obesity.The present invention is further illustrated by the following examples which, however, are notto be construed as limiting the scope of protection. The features disclosed in the foregoingdescription and in the following examples may, both separately and in any combinationthereof. be material for realising the invention in diverse forms thereof.EXAMPLESThe following acronyms for commercially available chemicals are used:DMF : N,N—Dimethylformamide.NMP 2 N-Methyl-2-pyrrolidone.EDPA : N-Ethyl—N,N-diisopropylamine.EGTA : Ethylene glycol—bis(B-aminoethyl ether)~N,N,N’,N’-tetraaceticacid.GTP Guanosine 5’—triphosphate.TFA : Trifluoroacetic acid.THF : Tetrahyd rofuran101520253035CA 02264243 1999-02-25wo 98/08871 PCT/DK97/0034037Myr-ONSu: Tetradecanoic acid 2,5-dioxopyrrolidin-1-yl ester.Pal-ONSu: Hexadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.Ste-ONSu Octadecanoic acid 2,5-dioxopyrrolidin-1~yl ester.HOOC~(CH_,_)6-COONSu:HOOC—(CH2),0-COONSu:HOOC-(CH2)12-COONSU:HOOC-(CH2),4-COONSU:HOOC-(CH2),6-COONSu:HOOC-(CH2).8-COONSu:o)—Carboxyheptanoic acid 2,5-dioxopyrrolidin-1-yl ester.co—Carboxyundecanoic acid 2,5-dioxopyrrolidin-1-yl ester.cn—Carboxytridecanoic acid 2,5-dioxopyrrolidin-1-yl ester.co—Carboxypentadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.co—Carboxyheptadecanoic acid 2,5~dioxopyrro|idin—1-yl ester.co—Carboxynonadecanoic acid 2.5-dioxopyrrolidin-1-yl ester.Abbreviations:PDMS: Plasma Desorption Mass SpectrometryMALDl-MS: Matrix Assisted Laser Desorption/ionisation Mass SpectrometryHPLC: High Performance Liquid Chromatographyamu: atomic mass unitsAnalyticalPlasma Desorption Mass SpectrometrySample preparation:The sample is dissolved in 0.1 % TFAlEtOH (1:1) at a concentration of 1 pg/pl. Thesample solution (5-10 ul) is placed on a nitrocellulose target (Bio-ion AB, Uppsala.Sweden) and allowed to adsorb to the target surface for 2 minutes. The target issubsequently rinsed with 2x25 ul 0.1 % TFA and spin-dried. Finally, the nitrocellulosetarget is placed in a target carrousel and introduced into the mass spectrometer.M I is:PDMS analysis was carried out using a Bio-ion 20 time-of flight instrument (Bio-ion NordicAB, Uppsala, Sweden). An acceleration voltage of 15 kV was applied and molecular ionsformed by bombardment of the nitrocellulose surface with 252-Cf fission fragments wereaccelerated towards a stop detector. The resulting time-of—flight spectrum was calibrated.. .......,..,,............................._.,........,.............. _.......... ................................................... . . .. . .10152530CA 02264243 2001-05-28W0 98/082371 PCT /DK97I0034038into a true mass spectrum using the H’ and NO’ ions at mlz 1 and 30, respectively. Massspectra were generally accumulated for 1.0x10° fission events corresponding to 15-20minutes. Resulting assigned masses all correspond to isotopically averaged molecularmasses. The accuracy of mass assignment is generally better than 0.1 %.MALDI-MSMALDI-TOF MS analysis_was carried out using a Voyagerm RP instrument (perSeptiveBiosystems Inc, Framingham, MA) equipped with delayed extraction and operated inlinear mode. Alpha—cyano—4-hydroxy-cinnamic acid was used as matrix, and massassignments were based on external calibration.Example 1Synthesis of Lys’°(N‘-tetradecanoyl)-GLP-1(7-37).The title compound was synthesised from GLP-1(7-37). A mixture of GLP—1(7-37) (25 mg.7.45 pm), EDPA (26.7 mg, 208 pm), NMP (520 pl) and water (260 pl) was gently shakenfor 5 min. at room temperature. To the resulting mixture was added a solution of Myr-ONSu (2.5 mg, 7.67 pm) in NMP (62.5 pl). the reaction mixture was gently.shaken for 5min. at room temperature and then allowed to stand for 20 min. An additional amount ofMyr-ONSu (2.5 mg. 7.67 pm) in NMP (62.5 pl) was added and the resulting mixture gentlyshaken for 5 min. After a total reaction time of 40 min. the reaction was quenched by theaddition of a solution of glycine (12.5 mg. 166 pmol) in 50% aqueous ethanol (12.5 ml).The title compound was isolated from the reaction mixture by HPLC using a cyanopropylcolumn (Zorbax"" 300SB-CN) and a standard acetonitrile/T FA system, yield: 1.3 mg(corresponding to 4.9% of the theoretical yield). The column was heated to 65°C and theacetonitrile gradient was 0-100% in 60 minutes. The isolated product was analysed byPDMS and the mlz value for the protonated molecular ion was found to be 3567.913. Theresulting molecular weight is thus 3566.9-:3 amu (theoretical value: 3565.9 amu). Theposition of acylation (Lys26) was verified by enzymatic cleavage of the title compound withStaphylococcus aureus V8 protease and subsequent mass determination of the peptidefragments by PDMS.1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034039In addition to the title compound two other GLP-1 derivatives were isolated from thereaction mixture by using the same chromatographic column and a more shallow gradient(35-38% acetonitrile in 60 minutes), see Examples 2 and 3.Example 2Synthesis of Lys3“(N‘-tetradecanoyl)-GLP-1 (7-37).The title compound was isolated by HPLC from the reaction mixture described in Example1. PDMS analysis yielded a protonated molecular ion at m/z 3567.7i3. The molecularweight is thus found to be 3566.713 amu (theoretical value: 3565.9 amu). The acylationsite was determined on the basis of the fragmentation pattern.Example 3Synthesis of Lys"'”“—bis(N‘-tetradecanoyl)-GLP-1(7-37).The title compound was isolated by HPLC from the reaction mixture described in Example1. PDMS analysis yielded a protonated molecular ion at m/z 3778.4.t3. The molecularweight is thus found to be 3777.413 amu (theoretical value: 3776.1 amu).Example 4Synthesis of Lys25(N‘-tetradecanoyl)Arg3"-GLP-1(7-37).The title compound was synthesised from Arg“-GLP-1(7-37). A mixture of Arg“-GLP-1(7-37) (5 mg, 1.47 pm), EDPA (5.3 mg, 41.1 um), NMP (105 pl) and water (50 ul) was gentlyshaken for 5 min. at room temperature. To the resulting mixture was added a solution ofMyr-ONSu (0.71 mg, 2.2 pm) in NMP (17.8 pl), the reaction mixture was gently shaken for5 min. at room temperature and then allowed to stand for 20 min. After a total reactiontime of 30 min. the reaction was quenched by the addition of a solution of glycine (25 mg,33.3 pm) in 50% aqueous ethanol (2.5 ml). The reaction mixture was purified by HPLC asdescribed in Example 1. PDMS analysis yielded a protonated molecular ion at m/z3594.913. The molecular weight is thus found to be 3593.9-.l:3 amu (theoretical value:3593.9 amu)...s.........w_.,.m.. ...... ........_.........-...»..... ........... .. .c.m.._..._......._.,.,. .... .1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034040Example 5Synthesis of Gly“Arg’°'3‘Lys“‘(N‘-tetradecanoyl)-GLP-1 (7-37).The title compound was synthesised from Gly“Arg25'3‘Lys35-GLP—1(7-37) which waspurchased from QCB. A mixture of Gly"Arg25"*“Lys°‘"’-GLP-1 (7-37) (1.3 mg, 0.39 pm), EDPA(1.3 mg, 10 pm), NMP (125 pl) and water (30 pl) was gently shaken for 5 min. at roomtemperature. To the resulting mixture was added a solution of Myr-ONSu (0.14 mg, 0.44pm) in NMP (3.6 ml), the reaction mixture was gently shaken for 15 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (0.1 mg,1.33 pm) in 50% aqueous ethanol (10 pl). The reaction mixture was purified by HPLC, andthe title compound (60 pg, 4%) was isolated.Example 6Synthesis of Arg2“‘Lys35 (Nfitetradecanoyl)-GLP-1(7-37)-OH.A mixture of Arg2”‘Lys35-GLP-1(7-37)-OH (5.0 mg, 1.477 pmol), EDPA (5.4 mg, 41.78pmol), NMP (105 pl) and water (50 pl) was gently shaken for 5 min. at room temperature. .To the resulting mixture was added a solution of Myr-ONSu (0.721 mg, 2.215 pmol) inNMP (18 pl). The reaction mixture was gently shaken for 5 min. at room temperature, andthen allowed to stand for an additional 45 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.5 mg, 33.3 pmol) in 50% aqueousethanol (250 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 300SB—CN) and a standard acetonitrile/TFA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. Thetitle compound ( 1.49 mg. 28 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3595 : 3. The resultingmolecular weight is thus 3594 1 3 amu (theoretical value 3594 amu).Example 7Synthesis of Lys25'3“bis(N‘-(co—carboxynonadecanoyl))-GLP-1(7-37)-OH.A mixture of GLP-1(7-37)—OH (70 mg, 20.85 pmol), EDPA (75.71 mg, 585.8 pmol), NMP(1.47 ml) and water (700 pL) was gently shaken for 10 min. at room temperature. To the1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034041resulting mixture was added a solution of HOOC-(CH2),,,-COONSU (27.44 mg, 62.42 umol)in NMP (686 iii), the reaction mixture was gently shaken for 5 min. at room temperature,and then allowed to stand for an additional 50 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (34.43 mg, 458.? umol) in 50% aqueousethanol (3.44 ml). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 30OSB-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100"/o in 60 minutes. Thetitle compound ( 8.6 mg, 10 °/o) was isolated, and the product was analysed by PDMS. Them/z value for the protonated molecular ion was found to be 4006 i 3. The resultingmolecular weight is thus 4005 i 3 amu (theoretical value 4005 amu).Example 8Synthesis of Arg2“‘Lys3“(N‘-(orcarboxynonadecanoyl))-GLP—1(7-36)-OH.A mixture of Arg”-°‘Lys35-GLP-1(7-36)-OH (5.06 mg, 1.52 umol), EDPA (5.5 mg, 42.58umol), NMP (106 pl) and water (100 pl) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution of HOOC-(CH2),,,—COONSu (1.33 mg, 3.04umol) in NMP (33.2 pl), the reaction mixture was gently shaken for 5 min. at roomtemperature, and then allowed to stand for an additional 2.5 h at room temperature. Thereaction was quenched by the addition of a solution of glycine (2.50 mg, 33.34 umol) in50% (250 ul). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 30088-CN) and a standardacetonitrilefl" FA system. The column was heated to 65°C and the acetonitrile gradient wasaqueous ethanol0-100% in 60 minutes. The title compound ( 0.46 mg, 8 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3652 i 3. The resulting molecular weight is thus 3651 : 3 amu (theoretical value 3651amu).Example 9Synthesis of Argzs-3‘Lys3°(N‘-(u)-carboxynonadecanoyl))-GLP-1(7-38)-OH.A mixture of Argze-3‘Lys3°-GLP-1(7~38)—OH (5.556 mg, 1.57umol), EDPA (5.68 mg, 43.96umol), NMP (116.6 pi) and water (50 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixturewas added a solution HOOC-(CH2),,,-COONSu (1.381015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97I0034042mg, 3.14 umol) in NMP (34.5 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 2.5 h at room temperature.The reaction was quenched by the addition of a solution of glycine (2.5 mg, 33.3 umol) in50% aqueous ethanol (250 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 3OOSB-CN) and a standardacetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was0—100% in 60 minutes. The m_<a_cQmpgmg (0.7 mg, 12 %) was isolated. and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3866 : 3. The resulting molecular weight is thus 3865 : 3 amu (theoretical value 3865amu).Example 10Synthesis of Arg3‘Lys25 (N‘-(u)—carboxynonadecanoyl))-GLP-1(7-37)-OH.A mixture of Arg“-GLP-1(7-37)-OH (5.04 mg, 1.489 umol), EDPA (5.39 mg, 41.70 umol),NMP (105 pi) and water (50 pl) was gently shaken for 10 min. at room temperature. To theresulting mixture was added a solution HOOC-(CH2)15-COONSU (1.31 mg, 2.97 umol) inNMP (32.8 ul), the reaction mixture was gently shaken for 5 min. at room temperature, andthen allowed to stand for an additional 30 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.46 mg, 32.75 umol) in 50% aqueousethanol (246 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 3OOSB-CN) and a standard acetonitrilefl”FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0—100% in 60 minutes. Thetitle ggmpgund ( 1.2 mg, 22 %) was isolated, and the product was analysed by PDMS. Them/z value for the protonated molecular ion was found to be 3709 :r 3. The resultingmolecular weight is thus 3708 1 3 amu (theoretical value 3708 amu).Example 11Synthesis of Arg3“i_ys2" (N‘-(co—carboxyheptadecanoyl))—GLP-1(7-37)-OH.A mixture of Arg“-GLP-1(7-37)-OH (5.8 mg, 1.714 umol), EDPA (6.20 mg, 47.99 pmol).NMP (121.8 pl) and water (58 ul) was gently shaken for 10 min. at room temperature. Tothe resulting mixture was added a solution HOOC-(CH2),5-COONSu (2.11 mg, 5.142 pmol)in NMP (52.8 pl), the reaction mixture was gently shaken for 5 min. at room temperature,1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97I0034043and then allowed to stand for an additional 2 h at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.83 mg, 37.70 pmol) in 50% aqueousethanol (283 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 300SB-CN) and a standard acetonitrile/'l' FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. The d (0.81 mg, 13 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3681 i 3. The resultingmolecular weight is thus 3680 : 3 amu (theoretical value 3680 amu).Example 12Synthesis of Arg26'3‘Lys3“ (N‘-(u)—carboxyheptadecanoyl))—GLP-1(7-37)-OH.A mixture of ArgZ°'°‘Lys35-GLP-1(7-37)-OH (3.51 mg. 1.036 pmol), EDPA (3.75 mg, 29.03pmol), NMP (73.8 pi) and water (35 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC-(CH2),,,-COONSu (1.27mg, 3.10 pmol) in NMP (31.8 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 2 h and 10 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (1.71 mg,22.79 pmol) in 50% aqueous ethanol (171 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 3008B-CN) and a standardacetonitrileff FA system. The column was heated to 65°C and the acetonitrile gradient wasO-100% in 60 minutes. The title gomggund (0.8 mg, 21 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3682 : 3. The resulting molecular weight is thus 3681 t 3 amu (theoretical value3681amu).Example 13Synthesis of Argm‘Lys”(N‘-(cn—carboxyheptadecanoyl))-GLP-1(7-38)-OH.A mixture of Arg2“'3‘Lys”-GLP-1(7-38)-OH (5.168 mg, 1.459 pmol), EDPA (5.28 mg, 40.85pmol), NMP (108.6 pl) and water (51.8 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC-(CH2),6-COONSu (1.80mg, 4.37 pmol) in NMP (45 pl), the reaction mixture was gently shaken for 10 min. at roomtemperature, and then allowed to stand for an additional 2 h and 15 min. at room1015202530CA 02264243 1999-02-25WO 98108871 PCT/DK97/0034044temperature. The reaction was quenched by the addition of a solution of glycine (2.41 mg,32.09 pmol) in 50% aqueous ethanol (241 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standardacetonitrile/TFA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title c m nd (0.8 mg, 14 °/o) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3838 i 3. The resulting molecular weight is thus 3837 : 3 amu (theoretical value 3837amu).Example 14Synthesis of Arg25'3‘Lys35 (N‘-(co—carboxyheptadecanoyl))—GLP-1(7-36)-OH.A mixture of Arg2“'3‘Lys35—GLP-1(7-36)-OH (24.44 mg, 7.34 pmol), EDPA (26.56 mg,205.52 pmol), NMP (513 pl) and water (244.4 pl) was gently shaken for 5 min. at roomtemperature. To the resulting mixture was added a solution HOOC-(CH2),5-COONSU (9.06mg, 22.02 pmol) in NMP (1.21 ml), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 30 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (12.12mg, 161.48 pmol) in 50% aqueous ethanol (1.21 ml). The reaction mixture was purified bycolumn chromatography using a cyanopropyl column (Zorbax 300SB—CN) and a standardacetonitrile/TFA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (7.5 mg, 28 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3625 1 3. The resulting molecular weight is thus 3624 :r 3 amu (theoretical value 3624amu).Example 15Synthesis of Argzfi-“Lys” (N‘—(co—carboxyundecanoyl))—GLP-1(7-37)—OH.A mixture of Argze-“Lyssa-GLP-1(7-37)-OH (4.2 mg, 1.24 pmol), EDPA (4.49 mg, 34.72pmol), NMP (88.2 pl) and water (42 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC-(CH2),o-COONSu (1.21mg, 3.72 pmol) in NMP (30.25 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 40 min. at room1015202530CA 02264243 1999-02-25WO 98/08371 PCT/DK97/0034045temperature. The reaction was quenched by the addition of a solution of glycine (2.04 mg,27.28 pmol) in 50% aqueous ethanol (204 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standardacetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (0.8 mg, 18 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3598 i 3. The resulting molecular weight is thus 3597 i 3 amu (theoretical value 3597amu).Example 16Synthesis of Argm‘Lys3°(N‘—(w—carboxyundecanoyl))-GLP-1(7-38)—OH.A mixture of Arg2‘""3‘Lys3“-GLP-1(7-38)-OH (5.168 mg, 1.46 pmol), EDPA (5.28 mg, 40.88pmol), NMP (108.6 pl) and water (51.7 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC—(CH2),,,-COONSu (1.43mg, 4.38 pmol) in NMP (35.8 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 50 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (2.41 mg,32.12 pmol) in 50% aqueous ethanol (241 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 300SB—CN) and a standardacetonitrile/TFA system. The column was heated to 65°C and the acetonitrile gradient wasO-100% in 60 minutes. The title compgund (0.85 mg, 16 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3753 i 3. The resulting molecular weight is thus 3752 : 3 amu (theoretical value 3752amu).Example 17Synthesis of Lys2““bis(N‘-(co—carboxyundecanoyl))-GLP-1(7-37)-OH.A mixture of GLP-1(7-37)-OH (10.0 mg, 2.98 pmol), EDPA (10.8 mg, 83.43 pmol), NMP(210 pl) and water (100 pl) was gently shaken for 10 min. at room temperature. To theresulting mixture was added a solution HOOC-(CH2),,,-COONSu (2.92 mg, 8.94 pmol) inNMP (73 pl), the reaction mixture was gently shaken for 5 min. at room temperature, andthen allowed to stand for an additional 50 min. at room temperature. The reaction was1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034046quenched by the addition of a solution of glycine (4.92 mg, 65.56 pmol) in 50% aqueousethanol (492 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 3OOSB-CN) and a standard acetonitrilefl'FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. Thetitle compound (1.0 mg, 9 %) was isolated, and the product was analysed by PDMS. Them/z value for the protonated molecular ion was found to be 3781 i 3. The resultingmolecular weight is thus 3780 : 3 amu (theoretical value 3780amu).Example 18Synthesis of Arg2°'3‘Lys35 (N‘-(cwcarboxyundecanoyl))-GLP-1(7—36)—OH.A mixture of Arg2“~3‘Lys35-GLP-1(7-36)-OH (15.04 mg, 4.52 pmol), EDPA (16.35 mg,126.56 pmol), NMP (315.8 pl) and water (150.4 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC-(CH2),o-COONSu (4.44mg, 1356 pmol) in NMP (111 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 40 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (7.5 mg,99.44 pmol) in 50% aqueous ethanol (750 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 3OOSB-CN) and a standardacetonitrilefTFA system. The column was heated to 65°C and the acetonitrile gradient wasO-100% in 60 minutes. The title compound (3.45 mg, 22 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3540 i 3. The resulting molecular weight is thus 3539 1 3 amu (theoretical value 3539amu).Example 19Synthesis of Arg3“Lys26 (N‘-(u>—carboxyundecanoyl))-GLP-1(7-37)-OH.A mixture of Arg3“-GLP-1(7-37)-OH (5.87 mg, 1.73 pmol), EDPA (6.27 mg, 48.57 pmol),NMP (123.3 pl) and water (58.7 pl) was gently shaken for 10 min. at room temperature. Tothe resulting mixture was added a solution HOOC-(CH2),0-COONSU (1.70 mg, 5.20 pmol)in NMP (42.5 pl), the reaction mixture was gently shaken for 5 min. at room temperature,and then allowed to stand for an additional 40 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.86 mg, 286 pmol) in 50% aqueous1015202530CA 02264243 1999-02-25W0 93/03371 PCT/DK97/0034047ethanol (286 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 300SB-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. Thetitle compound (1.27 mg, 20 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3597 1 3. The resultingmolecular weight is thus 3596 i 3 amu (theoretical value 3596 amu).Example 20Synthesis of Arg3“Lys2° (N‘-(co—carboxyheptanoyl))-GLP-1(7-37)-OH.A mixture of Arg“-GLP-1(7-37)-OH (4.472 mg, 1.32 pmol), EDPA (4.78 mg, 36.96 pmol),NMP (94 pl) and water (44.8 pl) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution HOOC-(CH2)5-COONSU (1.07 mg, 3.96 pmol) inNMP (26.8 pl), the reaction mixture was gently shaken for 5 min. at room temperature, andthen allowed to stand for an additional 1 h and 50 min. at room temperature. The reactionwas quenched by the addition of a solution of glycine (2.18 mg, 29.04 pmol) in 50%aqueous ethanol (218 pl). The reaction mixture was purified by column chromatographyusing a cyanopropyl column (Zorbax 300SB—CN) and a standard acetonitrile/T FA system.The column was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes.The title compound (0.5 mg, 11 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3540 : 3. The resultingmolecular weight is thus 3539 : 3 amu (theoretical value 3539 amu).Example 21Synthesis of Arg25'3‘Lys°‘(N‘-(co—carboxyheptanoy|))-GLP-1(7-38)-OH.A mixture of Argze-3‘Lys3°-GLP—1(7-38)-OH (5.168 mg, 1.459 pmol), EDPA (5.28 mg, 40.85pmol), NMP (108.6 pl) and water (51.6 pl) was gently shaken for 10 min. at roomtemperature. To the resulting mixture was added a solution HOOC—(CH2)5-COONSu (1.18mg, 4.37 pmol) in NMP (29.5 pl), the reaction mixture was gently shaken for 5 min. atroom temperature, and then allowed to stand for an additional 1 h and 50 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (2.40 mg,32.09 pmol) in 50% aqueous ethanol (240 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 30088-CN) and a standard1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97/0034048acetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The t_itIe_c_Q_r_r_1p9ur_ig (0.5 mg, 9 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3697 : 3. The resulting molecular weight is thus 3695 i 3 amu (theoretical value 3695amu).Example 22Synthesis of Arg2““Lys“6 (N‘-(co—carboxyheptanoyl))-GLP-1(7-37)—OH.A mixture of Arg2°'3‘Lys35—GLP-1(7-37)-OH (5.00 mg, 1.47 pmol), EDPA (5.32 mg, 41.16umol), NMP (105 pi) and water (50 pl) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution HOOC-(CH2)6-COONSu (1.19 mg, 4.41umol) in NMP (29.8 pl), the reaction mixture was gently shaken for 5 min. at roomtemperature, and then allowed to stand for an additional 2 h at room temperature. Thereaction was quenched by the addition of a solution of glycine (2.42 mg, 32.34 pmol) in50% (242 pl).chromatography using a cyanopropyl column (Zorbax 300SB—CN) and a standardaqueous ethanol The reaction mixture was purified by columnacetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (0.78 mg, 15 °/0) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3542 i 3. The resulting molecular weight is thus 3541 : 3 amu (theoretical value 3541amu).Example 23Synthesis of Arg”-3‘Lys35 (N‘-(co—carboxyheptanoyl))-GLP-1(7-36)-OH.A mixture of Arg2“""Lys3'5-GLP—1(7-36)—OH (5.00 mg, 1.50 pmol), EDPA (5.44 mg, 42.08pmol), NMP (210 pi) and water (50 pl) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution HOOC-(CH2)6-COONSu (1.22 mg, 4.5 pmol)in NMP (30.5 pl), the reaction mixture was gently shaken for 5 min. at room temperature,and then allowed to stand for an additional 2 h at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.47 mg, 33.0 pmol) in 50% aqueousethanol (247 pl). The reaction mixture was purified by column chromatography using a1015202530CA 02264243 1999-02-25wo 98/08871 PCT/DK97/0034049cyanopropyl column (Zorbax 30OSB-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. Thetitle compound (0.71 mg, 14 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3484 i 3. The resultingmolecular weight is thus 3483 J_r 3 amu (theoretical value 3483 amu).Example 24Synthesis of Lys2°'3“bis(N‘-(o>—carboxyheptanoy|))-GLP—1(7-37)-OH.A mixture of GLP-1(7-37)-OH (10 mg, 2.5 pmol), EDPA (10.8 mg, 83.56 pmol), NMP (210pi) and water (100 pl) was gently shaken for 10 min. at room temperature. To the resultingmixture was added a solution HOOC—(CH2)6-COONSu (2.42 mg, 8.92 pmol) in NMP (60.5ul), the reaction mixture was gently shaken for 5 min. at room temperature, and thenallowed to stand for an additional 2 h and 35 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (4.92 mg, 65.54 umol) in 50% aqueousethanol (492 pl). The reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 30OSB-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was O-100% in 60 minutes. Thetitle compound (2.16 mg, 24 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3669 : 3. The resultingmolecular weight is thus 3668 : 3 amu (theoretical value 3668 amu).Example 25Synthesis of Arg3“Lys’5 (N‘-(m—carboxypentadecanoy|))—GLP-1(7-37)-OH.A mixture of Arg“-GLP-1(7-37)-OH (4.472 mg, 1.321 umol), EDPA (4.78 mg, 36.99 pmol),NMP (93.9 pl) and water (44.7 pl) was gently shaken for 10 min. at room temperature. Tothe resulting mixture was added a solution HOOC—(CH2),.—COONSu (1.519 mg, 3.963umol) in NMP (38 pl), the reaction mixture was gently shaken for 5 min. at roomtemperature, and then allowed to stand for an additional 1 h at room temperature. Thereaction was quenched by the addition of a solution of glycine (2.18 mg, 29.06 pmol) in50%chromatography using a cyanopropyl column (Zorbax 30OSB-CN) and a standardaqueous ethanol (218 pl). The reaction mixture was purified by columnacetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/00340500-100% in 60 minutes. The title comggund (0.58 mg, 12 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3654 i 3. The resulting molecular weight is thus 3653 -_t 3 amu (theoretical value 3653amu).Example 26Synthesis of Arg2°'3“Lys3° (N‘-(cn—carboxyheptanoy|))-GLP-1(7-36)-OH.A mixture of Arg26'3‘Lys35—GLP-1(7-36)-OH (5.00 mg, 1.50 umol), EDPA (5.44 mg. 42.08umol), NMP (210 pi) and water (50 ul) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution HOOC-(CH2),.,-COONSu (1.72 mg, 4.5umol) in NMP (43 ul), the reaction mixture was gently shaken for 5 min. at roomtemperature, and then allowed to stand for an additional 1 h at room temperature. Thereaction was quenched by the addition of a solution of glycine (2.48 mg, 33 umol) in 50%aqueous ethanol (248 pl). The reaction mixture was purified by column chromatographyusing a cyanopropyl column (Zorbax 300SB—CN) and a standard acetonitrilefT FA system.The column was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes.The title compound (0.58 mg, 11 %) was isolated, and the product was analysed byPDMS. The m/z value for the protonated molecular ion was found to be 3596 i 3. Theresulting molecular weight is thus 3595 i 3 amu (theoretical value 3595 amu).Example 27Synthesis of lithocholic acid 2,5-dioxo-pyrrolidin-1-yl ester.To a mixture of lithocholic acid (5.44 g, 14.34 mmol), N-hydroxysuccinimide (1.78 g, 15.0mmol), anhydrous THF (120 ml) and anhydrous acetonitrile (30 ml). kept at to 10 °C, wasadded a solution of N,N'-dicyclohexylcarbodiimide (3.44 g, 16.67 mmol) in anhydrous THF.The reaction mixture was stirred at ambient temperature for 16 h, filtered and concentratedin vaguo. The residue was dissolved in dichloromethane (450 ml), washed with a 10%aqueous Na2CO3 solution (2x150 ml) and water (2x150 ml), and dried (MgSO,,). Filteredand the filtrate concentrated in vagug to give a crystalline residue. The residue wasrecrystallised from a mixture of dichloromethane (30 ml) and n—heptane (30 ml to give thetitle compound (3.46 g, 51%) as a crystalline solid.1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034051Example 28Synthesis of Arg“Lys25(N‘-llthocholyl)-GLP-1(7-37)-OH.A mixture of Arg“-GLP-1(7-37)-OH (4.472 mg, 1.32 pmol), EDPA (4.78 mg, 36.96 pmol),NMP (94 pi) and water (44.8 pl) was gently shaken for 10 min. at room temperature. Tothe resulting mixture was added a solution of lithocholic acid 2,5-dioxo—pyrrolidin-1-yl ester(1.87 mg, 3.96 pmol) in NMP (46.8 pl), the reaction mixture was gently shaken for 5 min.at room temperature, and then allowed to stand for an additional 1 h at room temperature.The reaction was quenched by the addition of a solution of glycine (2.18 mg, 2904 pmol)in 50% aqueous ethanol (218 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 3OOSB—CN) and a standardacetonitrile/TFA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (1.25 mg, 25 %) was isolated, and the productwas analysed by PDMS. The m/2 value for the protonated molecular ion was found to be3744 +- 3. The resulting molecular weight is thus 3743 +- 3 amu (theoretical value 3743amu).Example 29Synthesis of N“-tetradecanoyl-Glu(ONSu)-OBu‘.To a suspension of H-Glu(OH)-OBu‘ (2.5 g, 12.3 mmol), DMF (283 ml) and EDPA (1.58 g,12.3 mmol) was added drop by drop a solution of Myr-ONSu (4.0 g, 12.3 mmol) in DMF(59 ml). The reaction mixture was stirred for 16 h at room temperature and thenconcentrated in vaggo to a total volume of 20 ml. The residue was partitioned between 5%aqueous citric acid (250 ml) and ethyl acetate (150 ml), and the phases were separated.The organic phase was concentrated in vague and the residue dissolved in DMF (40 ml).The resulting solution was added drop by drop to a 10% aqueous solution of citric acid(300 ml) kept at 0 “C. The precipitated compound was collected and washed with icedwater and dried in a vacuum drying oven. The dried compound was dissolved in DMF (23ml) and HONSu (1.5 g, 13 mmol) was added. To the resulting mixture was added asolution of N,N’-dicyclohexylcarbodiimide (2.44 g, 11.9 mmol) in dichloromethane (47 ml).The reaction mixture was stirred for 16 h at room temperature, and the precipitatedcompound was filtered off. The precipitate was recrystallised from n-heptane/2-propanol togive the title compound (3.03 g, 50%).1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034052Example 30Synthesis of Glu”-23'3°Arg25'3‘Lys“(N‘-(y-glutamyl(N“-tetradecanoyl)))-GLP-1 (7-38)-OH.A mixture of GIu22'23'3°Arg2“‘Lys”-GLP-1(7-38)-OH (1.0 mg, 0.272 pmol), EDPA (0.98 mg,7.62 pmol), NMP (70 pi) and water (70 pl) was gently shaken for 5 min. at roomtemperature. To the resulting mixture was added a solution of N"-tetradecanoyl-G|u(ONSu)-OBu‘, prepared as described in Example 29, (0.41 mg, 0.816 pmol) in NMP(10.4 pl), the reaction mixture was gently shaken for 5 min. at room temperature, and thenallowed to stand for an additional 45 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (0.448 mg, 5.98 pmol) in 50% aqueousethanol (45 pl). A 0.5 % aqueous solution of ammonium acetate (0.9 ml) was added, andthe resulting mixture was immobilised on a Varian 500 mg C8 Mega Bond Elut® cartridge,the immobilised compound washed with 5% aqueous acetonitrile (10 ml), and finallyliberated from the cartridge by elution with TFA (10 ml). The eluate was concentrated ig@QLI_O, and the reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 300SB-CN) and a standard acetonitrilefl'FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100"/o in 60 minutes. Thetitle compound (0.35 mg, 32 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 4012 i 3. The resultingmolecular weight is thus 4011 1 3 amu (theoretical value 4011 amu).Example 31Synthesis of Glu23'2°Arg““Lys3“(N‘—(y-glutamy|(N“-tetradecanoyl)))-GLP-1 (7-38)-OH.A mixture of Glu23'2“Arg°“‘Lys“"-GLP-1(7-38)-OH (6.07 mg, 1.727 pmol), EDPA (6.25 mg,48.36 pmol), NMP (425 pl) and water (425 pl) was gently shaken for 5 min. at roomtemperature. To the resulting mixture was added a solution of N°‘-tetradecanoy|-Glu(ONSu)-OBu‘ , prepared as described in example 29, (2.65 mg, 5.18 pmol) in NMP(66.3 pl), the reaction mixture was gently shaken for 5 min. at room temperature, and thenallowed to stand for an additional 45 min. at room temperature. The reaction wasquenched by the addition of a solution of glycine (2.85 mg, 38.0 pmol) in 50% aqueousethanol (285 pl). A 0.5 % aqueous solution of ammonium acetate (5.4 ml) was added, andthe resulting mixture was immobilised on a Varian 500 mg C8 Mega Bond Elut® cartridge,1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034053the immobilised compound washed with 5% aqueous acetonitrile (10 ml), and finallyliberated from the cartridge by elution with TFA (10 ml). The eluate was concentrated i_n_vacuo, and the reaction mixture was purified by column chromatography using acyanopropyl column (Zorbax 30088-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was O-100% in 60 minutes. Thetitl com nd (0.78 mg, 12 %) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3854 i 3. The resultingmolecular weight is thus 3853 i 3 amu (theoretical value 3853 amu).Example 32Synthesis of Lysm‘-bis(N‘-(cu-carboxytridecanoyl))-GLP-1(7-37)-OH.A mixture of GLP-1(7-37)-OH (30 mg, 8.9 umol), EDPA (32.3 mg, 250 pmol), NMP (2.1ml) and water (2.1 ml) was gently shaken for 5 min. at room temperature. To the resultingmixture was added a solution HOOC-(CH2),2-COONSU (12.7 mg, 35.8 umol) in NMP (318pl), the reaction mixture was gently shaken for 1 h and 40 min. at room temperature. Thereaction was quenched by the addition of a solution of glycine (3.4 mg, 44.7 umol) in 50%aqueous ethanol (335 pl). The reaction mixture was purified by column chromatographyusing a cyanopropyl column (Zorbax 3008B-CN) and a standard acetonitrile/T FA system.The column was heated to 85°C and the acetonitrile gradient was 0-100% in 60 minutes.The title compound (10 mg, 29 °/0) was isolated, and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3840 1 3. The resultingmolecular weight is thus 3839 t 3 amu (theoretical value 3839 amu).Example 33Synthesis of Lys25'3“-bis(N‘-(y-gIutamyl(N“-tetradecanoyl)))-GLP-1(7-37)-OH. (NNC 90-1167).A mixture of GLP-1(7-37)-OH (300 mg, 79.8 umol), EDPA (288.9 mg, 2.24 mmol), NMP(21 ml) and water (21 ml) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution of N“-tetradecanoyl-Glu(ONSu)-OBu‘, prepared asdescribed in Example 29, (163 mg, 319.3 pmol) in NMP (4.08 ml), the reaction mixturewas gently shaken for 5 min. at room temperature, and then allowed to stand for anadditional 1 h at room temperature. The reaction was quenched by the addition of a........_.....................—..u-.-................«__.-,..., . . . ......_...........».......i..-......_......».«....._., ... . .1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034054solution of glycine (131.8 mg, 1.76 mmol) in 50% aqueous ethanol (13.2 ml). A 0.5 %aqueous solution of ammonium-acetate (250 ml) was added, and the resulting mixture wasdivided into four equal portions. Each portion was eluted onto a Varian 500 mg C8 MegaBond Elut® cartridge, the immobilised compound washed with 0.1% aqueous TFA (3.5 ml),and finally liberated from the cartridge by elution with 70% aqueous acetonitrile (4 ml). Thecombined eluates were diluted with 0.1% aqueous TFA (300 ml). The precipitatedcompound was collected by centrifugation, washed with 0.1% aqueous TFA (50 ml), andfinally isolated by centrifugation. To the precipitate was added TFA (60 ml), and theresulting reaction mixture was stirred for 1 h and 30 min. at room temperature. ExcessTFA was removed in vacuo, and the residue was poured into water (50 ml). Theprecipitated compound was purified by column chromatography using a cyanopropylcolumn (Zorbax 3OOSB—CN) and a standard acetonitrile/TFA system. The column washeated to 65°C and the acetonitrile gradient was O-100% in 60 minutes. The titlecompound (27.3 mg, 8 %) was isolated, and the product was analysed by PDMS. The m/zvalue for the protonated molecular ion was found to be 4036 : 3. The resulting molecularweight is thus 4035 i 3 amu (theoretical value 4035 amu).Example 34Synthesis of Arg25'°“Lys3°(N‘-(arcarboxypentadecanoyl))-GLP-1(7-38)—OH.A mixture of Arg2““Lys°°-GLP-1(7-38)-OH (30 mg, 8.9 umol), EDPA (32.3 mg, 250 umol),NMP (2.1 ml) and water (2.1 ml) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution HOOC-(CH2)1,,-COONSU (13.7 mg, 35.8 umol) inNMP (343 pl), the reaction mixture was gently shaken for 1 h at room temperature. Thereaction was quenched by the addition of a solution of glycine (3.4 mg, 44.7 umol) in 50%aqueous ethanol (335 pl). The reaction mixture was purified by column chromatographyusing a cyanopropyl column (Zorbax 3OOSB—CN) and a standard acetonitrile/T FA system.The column was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes.The title compound (4.8 mg, 14 %) was isolated. and the product was analysed by PDMS.The m/z value for the protonated molecular ion was found to be 3894 : 3. The resultingmolecular weight is thus 3893 1 3 amu (theoretical value 3893 amu).1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97l0034055Example 35Synthesis of N“-hexadecanoyl-Glu(ONSu)-OBU‘.To a suspension of H-Glu(OH)-OBu‘ (4.2 g, 20.6 mmol), DMF (500 ml) and EDPA (2.65 g,20.6 mmol) was added drop by drop a solution of Pal-ONSu (7.3 g, 20.6 mmol) in DMF(100 ml). The reaction mixture was stirred for 64 h at room temperature and thenconcentrated L/;i_v_a&Q to a total volume of 20 ml. The residue was partitioned between10% aqueous citric acid (300 ml) and ethyl acetate (250 ml), and the phases wereseparated. The organic phase was concentrated in vacuo and the residue dissolved inDMF (50 ml). The resulting solution was added drop by drop to a 10% aqueous solution ofcitric acid (500 ml) kept at 0 °C. The precipitated compound was collected and washedwith iced water and dried in a vacuum drying oven. The dried compound was dissolved inDMF (45 ml) and HONSu (2.15 g, 18.7 mmol) was added. To the resulting mixture wasadded a solution of N,N'-dicyclohexylcarbodiimide (3.5 g, 17 mmol) in dichloromethane (67ml). The reaction mixture was stirred for 16 h at room temperature, and the precipitatedcompound was filtered off. The precipitate was recrystallised from n—heptane/2-propanol togive the title compound (6.6 g, 72%).Example 36Synthesis of Lys2“""‘-bis(N‘-(y-glutamyl(N“-hexadecanoyl)))-GLP-1(7-37)-OH.A mixture of GLP-1(7-37)-OH (10 mg, 2.9 umol). EDPA (10.8 mg, 83.4 umol), NMP (0.7ml) and water (0.7 ml) was gently shaken for 5 min. at room temperature. To the resultingmixture was added a solution of N“-hexadecanoyl-Glu(ONSu)—OBu‘ , prepared asdescribed in Example 33, (163 mg, 319.3 umol) in NMP (4.08 ml), the reaction mixturewas gently shaken 1 h and 20 min. at room temperature. The reaction was quenched bythe addition of a solution of glycine (4.9 mg, 65.6 pmol) in 50% aqueous ethanol (492 pl).A 0.5 % aqueous solution of ammonium-acetate (9 ml) was added, and the resultingmixture eluted onto a Varian 1g C8 Mega Bond Elut® cartridge, the immobilised compoundwashed with 5% aqueous acetonitrile (10 ml). and finally liberated from the cartridge byelution with TFA (10 ml). The eluate was concentrated in vacuo, and the residue purifiedby column chromatography using a cyanopropyl column (Zorbax 30OSB—CN) and astandard acetonitrile/T FA system. The column was heated to 65°C and the acetonitrile1015202530CA 02264243 1999-02-25W0 98/08871 PCT/DK97/0034056gradient was O—100% in 60 minutes. The Qm;m (2.4 mg, 20 %) was isolated, andthe product was analysed by PDMS. The m/z value for the protonated molecular ion wasfound to be 4092 i 3. The resulting molecular weight is thus 4091 : 3 amu (theoreticalvalue 4091 amu).Example 37Synthesis of Arg3“Lys25(N‘-(y-glutamyl(N“-hexadecanoyl)))-GLP—1 (7-37)-OH.A mixture of Arg3“—GLP-1(7-37)-OH (3.7 mg, 1.1 umol), EDPA (4.0 mg, 30.8 umol),acetonitrile (260 pi) and water (260 pl) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution of N“-hexadecanoyl-Glu(ONSu)-OBu‘ ,prepared as described in Example 35, (1.8 mg, 3.3 umol) in acetonitrile (44.2 pi), and thereaction mixture was gently shaken for 1 h and 20 min. at room temperature. The reactionwas quenched by the addition of a solution of glycine (1.8 mg, 24.2 umol) in 50% aqueousethanol (181 pl). A 0.5 % aqueous solution of ammonium-acetate (12 ml) and NMP (300pl) were added, and the resulting mixture eluted onto a Varian 1g C8 Mega Bond Elut®cartridge, the immobilised compound washed with 5% aqueous acetonitrile (10 ml), andfinally liberated from the cartridge by elution with TFA (6 ml). The eluate was allowed tostand for 2 h at room temperature and then concentrated in vacuo. The residue waspurified by column chromatography using a cyanopropyl column (Zorbax 30OSB-CN) and astandard acetonitrile/TFA system. The column was heated to 65°C and the acetonitrilegradient was 0-100% in 60 minutes. The title compound (0.23 mg, 6 %) was isolated, andthe product was analysed by PDMS. The m/z value for the protonated molecular ion wasfound to be 3752 i 3. The resulting molecular weight is thus 3751 : 3 amu (theoreticalvalue 3751 amu).Example 38Synthesis of Arg25~3‘Lys3°(N‘-(y-glutamy|(N“-tetradecanoyl)))-GLP—1(7-38)-OH.A mixture of Arg“-"“Lys3"-GLP-1(7-38)-OH (14 mg, 4.0 umol), EDPA (14.3 mg, 110.6pmol), NMP (980 pl) and water (980 pl) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution of N“-tetradecanoyl-Glu(ONSu)-OBu’ ,prepared as described in Example 29, (12.1 mg, 23.7 umol) in NMP (303 pl), and thereaction mixture was gently shaken for 2 h at room temperature. The reaction was1015202530CA 02264243 1999-02-25wo 98108871 PCT/DK97/0034057quenched by the addition of a solution of glycine (6.5 mg, 86.9 mmol) in 50% aqueousethanol (652 pl). A 0.5 % aqueous solution of ammonium-acetate (50 (ml) was added, andthe resulting mixture eluted onto a Varian 1g C8 Mega Bond E|ut® cartridge, theimmobilised compound washed with 5% aqueous acetonitrile (15 ml), and finally liberatedfrom the cartridge by elution with TFA (6 ml). The eluate was allowed to stand for 1 h and45 min. at room temperature and then concentrated in_\4aooo. The residue was purified bycolumn chromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standardacetonitrile/T FA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (3.9 mg, 26 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3881 i 3. The resulting molecular weight is thus 3880 1 3 amu (theoretical value 3880amu).Example 39Synthesis of Argm“Lys°"(N‘-(co-carboxypentadecanoyl))-GLP-1(7-38)—OH.A mixture of Arg25'3‘Lys3“-GLP-1(7-38)-OH (14 mg, 4.0 pmol), EDPA (14.3 mg, 111 pmol),NMP (980 pl) and water (980 pl) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution of HOOC-(CH2)...-COONSu (4.5 mg, 11.9 pmol) inNMP (114 pl), the reaction mixture was gently shaken for 1 h and 45 min. at roomtemperature. An additional solution of HOOC-(CH2),.,-COONSu (4.0 mg, 10.4 pmol) inNMP (100 pl) was added, and the resulting mixture was gently shaken for an additional 1 hand 30 min. at room temperature. The reaction was quenched by the addition of a solutionof glycine (1.5 mg, 19.8 pmol) in 50% aqueous ethanol (148 pl). The reaction mixture waspurified by column chromatography using a cyanopropyl column (Zorbax 300SB-CN) and astandard acetonitrilefl” FA system. The column was heated to 65°C and the acetonitrilegradient was 0-100% in 60 minutes. The title comoound (3.9 mg, 26 %) was isolated, andthe product was analysed by PDMS. The m/z value for the protonated molecular ion wasfound to be 3809 1: 3. The resulting molecular weight is thus 3808 i 3 amu (theoreticalvalue 3808 amu).. . ..........................._.....e......... -.. .. .1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034058Example 40Synthesis of Arg25'3‘Lys"”(N‘-(y—glutamyl(N“-hexadecanoyl)))—GLP—1 (7-3'8)-OH.A mixture of Arg2°'3‘Lys°°—GLP-1(7-38)-OH (14 mg, 4.0 umol), EDPA (14.3 mg, 110.6pmol), NMP (980 pl) and water (980 ul) was gently shaken for 5 min. at room temperature.To the resulting mixture was added a solution of N“-hexadecanoyl-G|u(ONSu)-OBu‘ ,prepared as described in Example 35. (6.4 mg, 11.9 umol) in NMP (160 pi), and thereaction mixture was gently shaken for 1 h and 20 min. at room temperature. The reactionwas quenched by the addition of a solution of glycine (6.5 mg, 87 mmol) in 50% aqueousethanol (653 pl). A 0.5 % aqueous solution of ammonium-acetate (50 ml) was added, andthe resulting mixture eluted onto a Varian 1g C8 Mega Bond Elut® cartridge, theimmobilised compound washed with 5% aqueous acetonitrile (10 ml), and finally liberatedfrom the cartridge by elution with TFA (6 ml). The eluate was allowed to stand for 1 h and30 min. at room temperature and then concentrated in vacuo. The residue was purified bycolumn chromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standardacetonitrile/TFA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (7.2 mg, 47 %) was isolated, and the productwas analysed by PDMS. The m/z value for the protonated molecular ion was found to be3881 i 3. The resulting molecular weight is thus 3880 1 3 amu (theoretical value 3880amu).Example 41Synthesis of Arg""23-26'3°'3“Lys3”(N‘-hexadecanoyl)-GLP-1(7-38)-OH.A mixture of Arg‘“3'2“'°°'3“Lys°“’—GLP-1(7-38)-OH (1.0 mg, 0.27 umol), EDPA (0.34 mg, 2.7umol) and DMSO (600 pl) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution of Pal—ONSu (0.28 mg, 0.8 umol) in NMP (7 ul).The reaction mixture was gently shaken for 5 min. at room temperature, and then allowedto stand for an additional 6 h at room temperature. The reaction was quenched by theaddition of a solution of glycine (1.6 mg, 21.7 pmol) in 50% aqueous ethanol (163 pl). Thereaction mixture was purified by column chromatography using a cyanopropyl column(Zorbax 300SB-CN) and a standard acetonitrile/T FA system. The column was heated to65°C and the acetonitrile gradient was 0-100% in 60 minutes. The title comggimd ( 0.17mg, 16 %) was isolated, and the product was analysed by MALDI-MS. The m/z value for51015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/0034059the protonated molecular ion was found to be 3961 i 3. The resulting molecular weight isthus 3960 t 3 amu (theoretical value 3960 amu).Example 42Synthesis of Arg”-3‘Lys”(N‘-(tn-carboxytridecanoyl))-GLP-1(7-38)-OH.A mixture of Arg’°'3“Lys3"-GLP-1(7-38)—OH (14 mg, 4.0 umol), EDPA (14.3 mg, 111 umol),NMP (980 pi) and water (980 pl) was gently shaken for 5 min. at room temperature. To theresulting mixture was added a solution of HOOC-(CH2),2-COONSu (4.2 mg, 11.9 umol) inNMP (105 pl), the reaction mixture was gently shaken for 1 h and 50 min. at roomtemperature. The reaction was quenched by the addition of a solution of glycine (6.5 mg,87 umol) in 50% aqueous ethanol (652 pl). The reaction mixture was purified by columnchromatography using a cyanopropyl column (Zorbax 3OOSB-CN) and a standardacetonitri|efT FA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (5.8 mg, 39 %) was isolated, and the productwas analysed by MALDl—MS. The m/z value for the protonated molecular ion was found tobe 3780 i 3. The resulting molecular weight is thus 3779 : 3 amu (theoretical value 3781amu).Example 43Synthesis of Arg3‘Lys26(N‘-(y-glutamyl(N“—tetradecanoyl)))-GLP-1(7-37)—OH.A mixture of Arg3“-GLP-1(7-37)-OH (15 mg, 4.4 umol), EDPA (16 mg, 124 umol), NMP (2ml) and water (4.8 ml ) was gently shaken for 5 min. at room temperature. To the resultingmixture was added a solution of N“-tetradecanoyl—Glu(ONSu)-OBu‘ , prepared asdescribed in Example 29, (12.1 mg, 23.7 umol) in NMP (303 pi), and the reaction mixturewas gently shaken for 2 h at room temperature. The reaction was quenched by theaddition of a solution of glycine (6.5 mg, 86.9 umol) in 50% aqueous ethanol (652 pl). A0.5 % aqueous solution of ammonium-acetate (50 ml) was added, and the resultingmixture eluted onto a Varian 1g C8 Mega Bond Elut® cartridge, the immobilised compoundwashed with 5% aqueous acetonitrile (15 ml), and finally liberated from the cartridge byelution with TFA (6 ml). The eluate was allowed to stand for 1 h and 45 min. at roomtemperature and then concentrated in vacuo. The residue was purified by column..........w..l..u.......A.....__.......—........_....._.. .. .1015202530CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034060chromatography using a cyanopropyl column (Zorbax 300SB-CN) and a standardacetonitrilefTFA system. The column was heated to 65°C and the acetonitrile gradient was0-100% in 60 minutes. The title compound (3.9 mg, 26 %) was isolated, and the productwas analysed by MALDI-MS. The m/z value for the protonated molecular ion was found tobe 3723 i 3. The resulting molecular weight is thus 3722 :5 3 amu (theoretical value 3723amu).Example 44Synthesis of N“-octadecanoyl-Glu(ONSu)-OBu‘.To a suspension of H-Glu(OH)-OBu‘(2.82 g, 13.9 mmol), DMF (370 ml) and EDPA (1.79 g,13.9 mmol) was added drop by drop a solution of Ste-ONSu (5.3 g, 13.9 mmol) in DMF (60ml). Dichloromethane (35 ml) was added, and the reaction mixture was stirred for 24 h atroom temperature and then concentrated in vaguo. The residue was partitioned between10% aqueous citric acid (330 ml) and ethyl acetate (200 ml), and the phases wereseparated. The organic phase was concentrated in vagug and the residue dissolved inDMF (60 ml). The resulting solution was added drop by drop to a 10% aqueous solution ofcitric acid (400 ml) kept at 0 °C. The precipitated compound was collected and washedwith iced water and dried in a vacuum drying oven. The dried compound was dissolved inDMF (40 ml) and HONSu (1.63 g, 14.2 mmol) was added. To the resulting mixture wasadded a solution of DCC (2.66 g, 12.9 mmol) in dichloromethane (51 ml). The reactionmixture was stirred for 64 h at room temperature, and the precipitated compound wasfiltered off. The precipitate was recrystallised from n-heptane/2-propanol to give the flt_le_compound (4.96 g, 68 %).Example 45Synthesis of Argze-3‘Lys3°(N‘-(y-glutamyl(N“-octadecanoyl)))-GLP-1(7-38)-OH.A mixture of Arg2°'3‘—GLP-1(7-38)—OH (28 mg, 7.9 pmol), EDPA (28.6 mg, 221.5 pmol),NMP (1.96 ml) and water (1.96 ml )was gently shaken for 5 min. at room temperature. Tothe resulting mixture was added a solution of N“-octadecanoyl-GIu(ONSu)-OBu‘ (17.93 g,31.6 pmol), prepared as described in Example 44, in NMP (448 pl), and the reactionmixture was gently shaken for 2 h at room temperature. The reaction was quenched by theaddition of a solution of glycine (13.1 mg, 174 pmol) in 50% aqueous ethanol (1.3 ml). A1015202530CA 02264243 1999-02-25wo 93/03371 PCT/DK97/00340610.5 % aqueous solution of ammonium—acetate (120 ml) was added, and the resultingmixture was divided into two equal portions. Each portion was eluted onto a Varian 5 g C8Mega Bond Elut® cartridge, the immobilised compound washed with 5% aqueousacetonitrile (25 ml), and finally liberated from the cartridge by elution TFA (25 ml). Thecombined eluates were allowed to stand for 1 h and 25 min. at room temperature and thenconcentrated in vaggg. The residue was purified by column chromatography using acyanopropyl column (Zorbax 300SB-CN) and a standard acetonitrile/T FA system. Thecolumn was heated to 65°C and the acetonitrile gradient was 0-100% in 60 minutes. Thetitle compound (3.6 mg, 11 %) was isolated, and the product was analysed by MALDI-MS.The m/z value for the protonated molecular ion was found to be 3940 i 3. The resultingmolecular weight is thus 3939 i 3 amu (theoretical value 3937 amu).BIOLOGICAL FINDINGSProtraction of GLP-1 derivatives after s.c. administrationThe protraction of a number GLP-1 derivatives of the invention was determined bymonitoring the concentration thereof in plasma after so administration to healthy pigs,using the method described below. For comparison also the concentration in plasma ofGLP-1(7-37) after so. administration was followed. The results are given in Table 1. Theprotraction of other GLP-1 derivatives of the invention can be determined in the same way.Pigs (50% Duroc, 25% Yorkshire, 25% Danish Landrace, app 40 kg) were fasted from thebeginning of the experiment. To each pig 0.5 nmol of test compound per kg body weightwas administered in a 50 pM isotonic solution (5 mM phosphate, pH 7.4, 0.02% Tween®-20 (Merck), 45 mg/ml mannitol (pyrogen free, Novo Nordisk). Blood samples were drawnfrom a catheter in vena jugularis at the hours indicated in Table 1. 5 ml of the bloodsamples were poured into chilled glasses containing 175 pl of the following solution: 0.18M EDTA, 1500 KIE/ml aprotinin (Novo Nordisk) and 3% bacitracin (Sigma), pH 7.4. Within30 min, the samples were centrifuged for 10 min at 5-6000*g. Temperature was kept at4°C. The supernatant was pipetted into different glasses and kept at minus 20°C until use.The plasma concentrations of the peptides were determined by RIA using a monoclonalantibody specific for the N-terminal region of GLP-1(7-37). The cross reactivities were lessCA 02264243 2001-05-28WO 98/08871 PCT/DK97/0034062than 1% with GLP-1(1-37) and GLP-1(8-36)amide and < 0.1% with GLP-1(9-37), GLP-1(10-36)amide and GLP—1(11~36)arnide. The entire procedure was carried out at 4°C.The assay was carried out as follows: 100 pl plasma was mixed with 271 pl 96% ethanol,.3 mixed using a vortex mixer and centrifuged at 2600'g for 30 min. The supernatantwasdecanted into Minisorp” tubes and evaporated completely (Savant speedvacw As290)_ Theevaporation residue was reconstituted in the assay buffer consisting of 80 mMNaH2PO./Na2HPO.. 0.1 % HSA (Orpha 20/21, Behring), 10 mM EDTA, 0.6 mM thiomersal(Sigma), pH 7.5. Samples were reconstituted in volumes suitable for their expected10 concentrations, and were allowed to reconstitute for 30 min. To 300 pl sample, 100 plantibody solution in -dilution buffer containing 40 mM NaH2PO./Na,HPO., 0.1 % HSA, 0.6mM thiomersal. pH 7.5, was added. A non-specific sample was prepared by mixing 300 plbuffer with 100 pl dilution buffer. Individual standards were prepared from freeze driedstocks, dissolved in 300 pl assay buffer. All samples were pre-incubated in Minisorp tubes15 with antibody as described above for 72 h. 200 pl tracer in dilution buffer containing 6-7000CPM was added, samples were mixed and incubated for 48 h. 1.5 ml of a suspension of200 ml per litre of heparin-stabilised bovine plasma and 18 g per litre of activated carbon(Merck) in 40 mM NaH2F’O./Na,HPO.. 0.6 mM thiomersal. pH 7.5, was added to eachtube. Before use, the suspension was mixed and allowed to stand for 2 h at 4°C. All210 samples were incubated for 1 h at 4°C and then centrifuged at 3400"g for 25 min.Immediately after the centrifugation. the supernatant was decanted and counted in a y-counter. The concentration in the samples was calculated from individual standard curves.The following plasma concentrations were found, calculated as % of the maximumconcentration for the individual compounds (n=2):2535101520CA 02264243 1999-02-25WO 98/08871 PCT/DK97/0034063Table 1Test Hours after so. administrationcompound"0.75 1 2 4 6 8 10 12 24GLP-1 (7-37) 100 9 1Example 25 73 92 100 98 82 24 16 16 16Example 17 76 71 91 100 84 68 30 9Example 43 39 71 93 100 91 59 50 17Example 37 26 38 97 100 71 81 80 45Example 11 24 47 59 71 100 94 100 94Example 12 36 54 65 94 80 100 85 93Example 32 55 53 90 83 88 70 98 100 100Example 14 18 25 32 47 98 83 97 100Example 13 15 22 38 59 97 85 100 76Example 38 60 53 100 66 48 39 25 29 0Example 39 38 100 70 47 33 33 18 27 14Example 40 47 19 50 100 51 56 34 14 0Example 34 19 32 44 84 59 66 83 84 100"The test compounds are the title compounds of the examples with the numbers givenAs it appears from Table 1, the GLP-1 derivatives of the invention have a protracted profileof action relative to GLP-1(7-37) and are much more persistent in plasma than GLP-1(7-37). it also appears from Table 1 that the time at which the peak concentration in plasma isachieved varies within wide limits, depending on the particular GLP-1 derivative selected.Stimulation of cAMP formation in a cell line expressing the cloned human GLP-1receptorIn order to demonstrate efficacy of the GLP-1 derivatives, their ability to stimulateformation of CAMP in a cell line expressing the cloned human GLP-1 receptor was tested.An EC5,, was calculated from the dose-response curve.Baby hamster kidney (BHK) cells expressing the human pancreatic GLP-1 receptor wereused (Knudsen and Pridal, 1996, Eur. J. Pharm. 318, 429-435). Plasma membranes wereprepared (Adelhorst et al, 1994, J. Biol. Chem. 269, 6275) by homogenisation in buffer (10mmol/l Tris-HCl and 30 mmol/l NaCl pH 7.4, containing, in addition, 1 mmol/l dithiothreitol, 5mg/l leupeptin (Sigma, St. Louis, MO, USA), 5 mg/l pepstatin (Sigma, St. Louis, MO, USA),100 mg/l bacitracin (Sigma, St. Louis, MO, USA), and 16 mg/l aprotinin (Novo Nordisk A/S,CA 02264243 1999-02-25W0 98/08871 PCT/DK97/0034064Bagsvaerd, Denmark)). The homogenate was centrifuged on top of a layer of 41 w/v%sucrose. The white band between the two layers was diluted in buffer and centrifuged.Plasma membranes were stored at -80°C until used.5 The assay was carried out in 96-well microtiter plates in a total volume of 140 pl. The bufferused was 50 mmol/I Tris-HCl, pH 7.4 with the addition of 1 mmol/l EGTA, 1.5 mmol/l MgSO,,.1.7 mmol/l ATP, 20 mM GTP, 2 mmol/I 3-isobutyl-1-methylxanthine, 0.01 % Tween-20 and0.1 % human serum albumin (Reinst, Behringwerke AG, Marburg, Germany). Compounds tobe tested for agonist activity were dissolved and diluted in buffer, added to the membrane10 preparation and the mixture was incubated for 2 h at 37°C. The reaction was stopped by theaddition of 25 ul of 0.05 mol/l HCl. Samples were diluted 10 fold before analysis for cAMP bya scintillation proximity assay (RPA 538, Amersham, UK). The following results were found:Test compound" EC50, pM Test compound" EC:-,0, pMGLP-1 (7-37) 61 Example 31 96Example 45 120 Example 30 41Example 43 24 Example 26 8.8Example 40 55 Example 25 99Example 39 5.1 Example 19 79Example 38 54 Example 16 3.5Example 37 6015 " The test compounds are the title compounds of the examples with the numbers given.CA 02264243 1999-08-2564aSEQUENCE LISTING(1) GENERAL INFORMATION:(i) APPLICANT: NOVO NORDISK A/S(ii) TITLE OF INVENTION: GLP-l DERIVATIVES(iii) NUMBER OF SEQUENCES: 96(iV) CORRESPONDENCE ADDRESS:(A) ADDRESSEE: SWABEY OGILVY RENAULT(B) STREET: 1981 McGill College Avenue, Suite 1600(C) CITY: Montréal(D) STATE: QC(E) COUNTRY: CANADA(F) ZIP: H3A 2Y3(V) COMPUTER READABLE FORM:(A) MEDIUM TYPE: Diskette(B) COMPUTER: IBM Compatible(C) OPERATING SYSTEM: Windows(D) SOFTWARE: FastSEQ for Windows Version 2.0b(vi) CURRENT APPLICATION DATA:(A) APPLICATION NUMBER: 2,264,243(B) FILING DATE: 22-AUG-1997(C) CLASSIFICATION:(Vii) PRIOR APPLICATION DATA:(A) APPLICATION NUMBER: DK 0931/96(B) FILING DATE: 30-AUG-1996(A) APPLICATION NUMBER: DK 1259/96(B) FILING DATE: 08—NOV—l996(A) APPLICATION NUMBER: DK 1470/96(B) FILING DATE: 20—DEC-1996(viii) ATTORNEY/AGENT INFORMATION:(A) NAME: Cété, France(B) REGISTRATION NUMBER: 4166(C) REFERENCE/DOCKET NUMBER: 11667-10 FC/ntb(ix) TELECOMMUNICATION INFORMATION:(A) TELEPHONE: 514-845-7126(B) TELEFAX: 514-288-8389(C) TELEX:(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acidCA 02264243 1999-08-2564b(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly20 25 30(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: proteinCA 02264243 1999-08-2564c(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:CA 02264243 1999-08-2564dHis Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Lys(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID N029:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:l0:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:l0:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15CA 02264243 1999-08-2564eGln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:ll:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Lys(2) INFORMATION FOR SEQ ID NO:l2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:l3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l3:CA 02264243 1999-08-2564fHis Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30Arg Lys(2) INFORMATION FOR SEQ ID NO:l4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l4:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly20 25 30(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30(2) INFORMATION FOR SEQ ID NO:l6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l6:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15CA 02264243 1999-08-2564gGln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:l8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:l8:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:l9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg LysCA 02264243 1999-08-2564h(2) INFORMATION FOR SEQ ID NO:20:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:21:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glyl 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly20 25 30(2) INFORMATION FOR SEQ ID NO:22:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:23:CA 02264243 1999-08-2564i(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Lys(2) INFORMATION FOR SEQ ID NO:24:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:25:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30Arg LysCA 02264243 1999-08-25543'(2) INFORMATION FOR SEQ ID NO:26:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Lys20 25 30(2) INFORMATION FOR SEQ ID NO:27:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:28:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Lys(2) INFORMATION FOR SEQ ID NO:29:CA 02264243 1999-08-2564k(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly15301 5 10Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25Arg Glu Lys35(2) INFORMATION FOR SEQ ID NO:30:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly15301 5 10Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25Arg Glu Phe Lys35(2) INFORMATION FOR SEQ ID NO:3l:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3l:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 1015Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25Arg Glu Phe Pro Lys3530CA 02264243 1999-08-25641(2) INFORMATION FOR SEQ ID NO:32:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glyl 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Glu Phe Pro Glu Lys35(2) INFORMATION FOR SEQ ID NO:33:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glyl 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30Arg Glu Phe Pro Glu Glu Lys35(2) INFORMATION FOR SEQ ID NO:34:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Lys35CA 02264243 1999-08-2564m(2) INFORMATION FOR SEQ ID NO:35:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear‘(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:36:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Arg Lys35 40(2) INFORMATION FOR SEQ ID NO:37:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 41 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30CA 02264243 1999-08-2564nVal Arg Gly Arg Gly Arg Arg Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:38:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 42 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Arg Glu Phe Lys35 40(2) INFORMATION FOR SEQ ID NO:39:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 43 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Arg Glu Phe Pro Lys35 40(2) INFORMATION FOR SEQ ID NO:40:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 44 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15CA 02264243 1999-08-25640Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Arg Glu Phe Pro Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:4l:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 45 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Arg Glu Phe Pro Glu Glu Lys35 40 45(2) INFORMATION FOR SEQ ID NO:42:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Lys35(2) INFORMATION FOR SEQ ID NO:43:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:CA 02264243 1999-08-2564pAsp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:44:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Arg Lys35(2) INFORMATION FOR SEQ ID NO:45:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Arg Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:46:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 41 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: proteinCA 02264243 1999-08-2564q(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Arg Glu Phe Lys35 40(2) INFORMATION FOR SEQ ID NO:47:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 42 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Arg Glu Phe Pro Lys35 40(2) INFORMATION FOR SEQ ID NO:48:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 43 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 10 15Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25 30Arg Gly Arg Gly Arg Arg Glu Phe Pro Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:49:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 44 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: proteinCA 02264243 1999-08-2564r(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser1 5 1015Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val20 25Arg Gly Arg Gly Arg Arg Glu Phe Pro Glu Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:50:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:30Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser15301 5 10Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25Gly Arg Gly Lys35(2) INFORMATION FOR SEQ ID NO:51:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1530l 5 10Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25Gly Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:52:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linearCA 02264243 1999-08-25645(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Lys35(2) INFORMATION FOR SEQ ID NO:53:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Glu Lys35(2) INFORMATION FOR SEQ ID NO:54:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Glu Phe Lys35 40(2) INFORMATION FOR SEQ ID NO:55:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 41 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linearCA 02264243 1999-08-2564t(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Glu Phe Pro Lys35 40(2) INFORMATION FOR SEQ ID NO:56:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 42 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID N0:56:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Glu Phe Pro Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:57:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 43 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser1 5 10 15Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg20 25 30Gly Arg Gly Arg Arg Glu Phe Pro Glu Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:58:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: singleCA 02264243 1999-08-2564u(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Lys35(2) INFORMATION FOR SEQ ID NO:59:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO 60:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyrl 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Lys35(2) INFORMATION FOR SEQ ID NO:6l:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acidCA 02264243 1999-08-2564V(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6l:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyrl 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Glu Lys35(2) INFORMATION FOR SEQ ID NO:62:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Glu Phe Lys35(2) INFORMATION FOR SEQ ID NO:63:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: Single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Glu Phe Pro Lys35 40(2) INFORMATION FOR SEQ ID NO:64:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 41 amino acidsCA 02264243 1999-08-2564w(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Glu Phe Pro Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:65:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 42 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr1 5 10 15Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly20 25 30Arg Gly Arg Arg Glu Phe Pro Glu Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:66:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Lys(2) INFORMATION FOR SEQ ID NO:67:(i) SEQUENCE CHARACTERISTICS:CA 02264243 1999-08-2564x(A) LENGTH: 35 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:68:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Lys35(2) INFORMATION FOR SEQ ID NO:69:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Glu Lys35(2) INFORMATION FOR SEQ ID NO:70:CA 02264243 1999-08-2564y(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Glu Phe Lys35(2) INFORMATION FOR SEQ ID NO:7l:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:7l:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Glu Phe Pro Lys35(2) INFORMATION FOR SEQ ID NO:72:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Glu Phe Pro Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:73:CA 02264243 1999-08-25642(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 41 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu1 5 10 15Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg20 25 30Gly Arg Arg Glu Phe Pro Glu Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:74:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Lys(2) INFORMATION FOR SEQ ID NO:75:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg LysCA 02264243 1999-08-2564aa(2) INFORMATION FOR SEQ ID NO:76:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg Arg Lys35(2) INFORMATION FOR SEQ ID NO:77:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg Arg Glu Lys35(2) INFORMATION FOR SEQ ID NO:78:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 S 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg Arg Glu Phe Lys35CA 02264243 1999-08-2564bb(2) INFORMATION FOR SEQ ID NO:79:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg Arg Glu Phe Pro Lys35(2) INFORMATION FOR SEQ ID NO:80:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30Arg Arg Glu Phe Pro Glu Lys35(2) INFORMATION FOR SEQ ID NO:81:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 40 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:8l:Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu1 5 10 15Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly20 25 30CA 02264243 1999-08-2564ccArg Arg Glu Phe Pro Glu Glu Lys35 40(2) INFORMATION FOR SEQ ID NO:82:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Lys Gly Arg Gly Lys35(2) INFORMATION FOR SEQ ID NO:83:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu20 ~ 25 30Val Arg Gly Arg Gly Lys35(2) INFORMATION FOR SEQ ID NO:84:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 38 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15CA 02264243 1999-08-2564ddSer Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Lys Gly Lys35(2) INFORMATION FOR SEQ ID NO:85:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Lys20 25 30(2) INFORMATION FOR SEQ ID NO:86:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Lys20 25 30(2) INFORMATION FOR SEQ ID NO:87:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Lys20 25 30CA 02264243 1999-08-2564ee(2) INFORMAT'ION FOR SEQ ID NO:88:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Lys20 25 30(2) INFORMATION FOR SEQ ID NO:89:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: s ingle(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Lys Gly Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:90:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Arg Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:91:CA 02264243 1999-08-2564ff(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val1 5 10 15Ser Ser Tyr Leu Glu Gly Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu20 25 30Val Arg Gly Lys Gly Arg Lys35(2) INFORMATION FOR SEQ ID NO:92:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID NO:93:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Arg20 25 30LysCA 02264243 1999-08-256499(2) INFORMAT'ION FOR SEQ ID NO:94:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Arg20 25 30Lys(2) INFORMATION FOR SEQ ID N0:95:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID N0:95:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Lys20 25 30(2) INFORMATION FOR SEQ ID NO:96:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1 5 10 15Gln Ala Ala Arg Glu Phe Ile Ala Trp Leu Val Arg Gly Lys Gly Lys20 25 30

Claims (40)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A GLP-1 derivative of formula I (SEQ ID NO:2):

His-Xaa-Xaa-Gly-Xaa-Phe-Thr-Xaa-Asp-Xaa-Xaa Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Phe Ile-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa wherein Xaa at position 8 is Ala, Xaa at position 9 is Glu, Xaa at position 11 is Thr, Xaa at position 14 is Ser, Xaa at position 16 is Val, Xaa at position 17 is Ser, Xaa at position 18 is Ser, Xaa at position 19 is Tyr, Xaa at position 20 is Leu, Xaa at position 21 is Glu, Xaa at position 22 is Gly, Xaa at position 23 is Gln, Xaa at position 24 is Ala, Xaa at position 25 is Ala, Xaa at position 26 is Lys, Xaa at position 27 is Glu, Xaa at position 30 is Ala, Xaa at position 31 is Trp, Xaa at position 32 is Leu, Xaa at position 33 is Val, Xaa at position 34 is Arg, Xaa at position 35 is Gly, Xaa at position 36 is Arg, and Xaa at position 37 is Gly, wherein (a) the .epsilon.-amino group of Lys at position 26 is substituted with a lipophilic substituent, optionally via a spacer, (b) the lipophilic substituent is (i) CH3(CH2)n CO - wherein n is 6, 8, 10, 12, 14, 16, 18, 20 or 22, (ii) HOOC(CH2)m CO - wherein m is 10, 12, 14, 16, 18, 20 or 22, or (iii) lithochoyl, and (c) the spacer is (i) an unbranched alkane .alpha.,.omega.-dicarboxylic acid group having from 1 to 7 methylene groups, (ii) an amino acid residue except Cys, or (iii) .gamma.-aminobutanoyl.
2. The GLP-1 derivative of claim 1, wherein the lipophilic substituent is linked to the .omega.-amino group of Lys via a spacer.
3. The GLP-1 derivative of claim 2, wherein the spacer is .gamma.-glutamyl.
4. The GLP-1 derivative of claim 2, wherein the spacer is .beta.-asparagyl.
5. The GLP-1 derivative of claim 2, wherein the spacer is glycyl.
6. The GLP-1 derivative of claim 2, wherein the .gamma.-aminobutanoyl.
7. The GLP-1 derivative of claim 2, wherein the .beta.-alanyl.
8. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon.-tetradecanoyl), Arg34-GLP-1(7-37).
9. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon.-(.omega.-carboxynonadecanoyl)), Arg34-GLP-1(7-37).
10. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.omega.-carboxyheptadecanoyl)), Arg34-GLP-1(7-37).
11. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.omega.-carboxyundecanoyl)), Arg34-GLP-1(7-37).
12. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.omega.-carboxypentadecanoyl)), Arg34-GLP-1(7-37).
13. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -lithochoyl),Arg34-GLP-1(7-37).
14. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.-glutamyl(N.alpha.-hexadecanoyl))), Arg34-GLP-1(7-37).
15. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.glutamyl(N.alpha. tetradecanoyl))), Arg34-GLP-1(7-37).
16. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.glutamyl(N.alpha. lithochoyl))), Arg34-GLP-1(7-37).
17. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.glutamyl(N.alpha. octadecanoyl))), Arg34-GLP-1(7-37).
18. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -decanoyl), Arg34-GLP-1(7-37).
19. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -hexadecanoyl), Arg34-GLP-1(7-37).
20. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -octanoyl), Arg34-GLP-1(7-37).
21. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -dodecanoyl), Arg34-GLP-1(7-37).
22. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. (N68 (.gamma.aminobutyroyl-(N.gamma.-hexadecanoyl))), Arg34-GLP-1(7-37).
23. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.-D
glutamyl(N.alpha.hexadecanoyl))), Arg34 -GLP-1(7-37).
24. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.glutamyl(N.alpha.-dodecanoyl))), Arg34-GLP-1(7-37).
25. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.beta.alanyl(N.alpha.-hexadecanoyl))), Arg34-GLP-1(7-37).
26. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.alpha.-glutamyl(N.alpha.-hexadecanoyl))), Arg34-GLP-1(7-37).
27. The GLP-1 derivative of claim 1, which is Lys26 (N.epsilon. -(.gamma.-glutamyl(N.alpha.-decanoyl))), Arg34-GLP-1(7-37).
28. A pharmaceutical composition comprising a GLP-1 derivative of claim 1 and a pharmaceutically acceptable vehicle or carrier.
29. A pharmaceutical composition of claim 28, further comprising an isotonic agent, a preservative and a buffer.
30. A pharmaceutical composition of claim 29, wherein the isotonic agent is sodium chloride, mannitol and glycerol.
31. A pharmaceutical composition of claim 29, wherein the preservative is phenol, m-cresol, methyl p-hydroxybenzoate or benzyl alcohol.
32. A pharmaceutical composition of claim 29, wherein the buffer is sodium acetate or sodium phosphate.
33. A pharmaceutical composition of claim 28, further comprising a surfactant.
34. A pharmaceutical composition of claim 28, further comprising zinc.
35. A pharmaceutical composition of claim 28, further comprising another antidiabetic agent.
36. A pharmaceutical composition of claim 35, wherein the antidiabetic agent is human insulin.
37. A pharmaceutical composition of claim 35, wherein the antidiabetic agent is a hypoglycemic agent.
38. A pharmaceutical composition of claim 28, further comprising another antiobesity agent.
39. Use of a derivative of any one of claims 1-27 for the preparation of a medicament for the treatment of diabetes.
40. Use of a derivative of any one of claims 1-27 for the preparation of a medicament for the treatment of obesity.
CA002264243A 1996-08-30 1997-08-22 Glp-1 derivatives Expired - Lifetime CA2264243C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2468374A CA2468374C (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK93196 1996-08-30
DK125996 1996-11-08
DK0931/96 1996-11-08
DK1259/96 1996-11-08
DK147096 1996-12-20
DK1470/96 1996-12-20
PCT/DK1997/000340 WO1998008871A1 (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2468374A Division CA2468374C (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Publications (2)

Publication Number Publication Date
CA2264243A1 CA2264243A1 (en) 1998-03-05
CA2264243C true CA2264243C (en) 2004-10-05

Family

ID=27221005

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002264243A Expired - Lifetime CA2264243C (en) 1996-08-30 1997-08-22 Glp-1 derivatives
CA2468374A Expired - Lifetime CA2468374C (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2468374A Expired - Lifetime CA2468374C (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Country Status (21)

Country Link
EP (2) EP1826216A1 (en)
JP (3) JP3149958B2 (en)
KR (1) KR100556067B1 (en)
CN (1) CN1271086C (en)
AT (1) ATE356830T1 (en)
BR (1) BRPI9711437B8 (en)
CA (2) CA2264243C (en)
CZ (1) CZ300837B6 (en)
DE (3) DE122009000079I2 (en)
DK (1) DK0944648T3 (en)
ES (1) ES2283025T3 (en)
FR (1) FR09C0054I2 (en)
HU (1) HU227021B1 (en)
IL (3) IL128332A0 (en)
NL (1) NL300422I2 (en)
NO (3) NO325273B1 (en)
PL (1) PL192359B1 (en)
PT (1) PT944648E (en)
RU (1) RU2214419C2 (en)
UA (1) UA72181C2 (en)
WO (1) WO1998008871A1 (en)

Families Citing this family (500)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0966297B2 (en) 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
DE122009000079I2 (en) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 DERIVATIVES
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002506792A (en) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N-terminal modified GLP-1 derivative
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1056775B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610599A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69942305D1 (en) * 1998-02-27 2010-06-10 Novo Nordisk As DERIVATIVES OF GLP-1 AND EXENDIN WITH EXTENDED DURABILITY PROFILE
JP2002504518A (en) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivatives with helix-content of more than 25% forming partially structured micellar-like aggregates
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP2002523333A (en) * 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Use of GLP-1 and analogs to prevent type II diabetes
WO2000012116A1 (en) * 1998-08-28 2000-03-09 Eli Lilly And Company Method for administering insulinotropic peptides
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly &amp; Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
JP2002524514A (en) 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー Protein preparation
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
KR100458748B1 (en) * 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Glp-1 analogues
PL189664B1 (en) * 1998-12-07 2005-09-30 Sod Conseils Rech Applic Analogues of glp-1
CZ295768B6 (en) 1998-12-07 2005-10-12 Societe De Conseils De Recherches Et D'application Analogues of GLP-1 having beta-alanine in position 35, their use and pharmaceutical compositions containing thereof
RU2242244C2 (en) * 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. New compositions of exendine agonists and methods of their administration
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1163268B1 (en) * 1999-03-15 2011-05-11 Novo Nordisk A/S Ion exchange chromatographic separation of glp-1 and related peptides
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
BR0009040A (en) * 1999-03-17 2001-12-18 Novo Nordisk As Method for acylating an amino group of a peptide or a protein, and, compound
JP4949557B2 (en) * 1999-03-17 2012-06-13 ノヴォ ノルディスク アー／エス Peptide acylation method and novel acylating agent
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CN1372570A (en) * 1999-04-30 2002-10-02 安米林药品公司 Modified exendin and exendin agonists
CN1191273C (en) 1999-05-17 2005-03-02 康久化学公司 Long lasting insulinotropic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
AU1269501A (en) * 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
JP2003525908A (en) 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ Low serum lipids
DE10013895A1 (en) 2000-03-21 2001-10-04 Dmc2 Degussa Metals Catalysts Cerdec Ag Process for the catalytic conversion of carbon monoxide in a gas mixture containing hydrogen
JP2004509079A (en) * 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド Modified biological peptides with increased potency
EP2062593A3 (en) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
CZ308214B6 (en) * 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fusion proteins
CZ20031732A3 (en) 2000-12-21 2003-09-17 Aventis Pharma Deutschland Gmbh 1,2-Diphenylazetidinones and pharmaceutical preparations containing thereof intended for treating lipid metabolism disorders
KR20030063462A (en) 2000-12-21 2003-07-28 아벤티스 파마 도이칠란트 게엠베하 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002235731A1 (en) * 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10142660A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of derivatives of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
JP2004529160A (en) * 2001-05-02 2004-09-24 ノボ・ノルデイスク・エー／エス Bile acid production
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
PE20021091A1 (en) 2001-05-25 2003-02-04 Aventis Pharma Gmbh DERIVATIVES OF PHENYLUREA SUBSTITUTED WITH CARBONAMIDE AND PROCEDURE FOR THEIR PREPARATION
PT1412384E (en) * 2001-06-28 2008-03-28 Novo Nordisk As Stable formulation of modified glp-1
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7595172B2 (en) * 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
KR20040032937A (en) 2001-08-22 2004-04-17 아벤티스 파마 도이칠란트 게엠베하 Combined preparations, containing 1, 4-benzothiepine-1, 1-dioxide derivatives and other active substances, and the use thereof
DE10142667B4 (en) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituted indan-1-oles and their derivatives and their use as medicines
DE10142668A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of C2-substituted indan-1-one systems for the preparation of medicaments for the prophylaxis or treatment of obesity
NZ531440A (en) 2001-08-31 2005-10-28 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10142663B4 (en) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituted indan-1-ol systems
DE10142659A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of multiply substituted indan-1-ol. Systems for the preparation of medicaments for the prophylaxis or treatment of obesity
DE10142661B4 (en) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Poly-substituted indan-1-ol systems and their use as pharmaceuticals
DE10142722A1 (en) 2001-08-31 2003-03-27 Aventis Pharma Deutschland GmbH, 65929 Frankfurt C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as medicaments
DE10142666A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
DE10142665B4 (en) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituted indan-1-ones and their derivatives
DE10142662B4 (en) 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivatives of C2-substituted indan-1-ol systems and their use as pharmaceuticals
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005514337A (en) * 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related diseases
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
AR038102A1 (en) * 2002-01-08 2004-12-29 Lilly Co Eli GLUCAGON TYPE 1 PEPTIDE EXTENDED ANALOGS
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP2329839B1 (en) * 2002-01-10 2015-09-16 Imperial Innovations Limited Modification of feeding behavior by GLP-1 and PYY
KR20040085205A (en) 2002-02-20 2004-10-07 일라이 릴리 앤드 캄파니 Method for administering glp-1 molecules
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
JP4881559B2 (en) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス Arylcarbonyl derivatives as therapeutic agents
CA2490564A1 (en) * 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10231370B4 (en) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
US7262220B2 (en) 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
WO2004007455A1 (en) 2002-07-12 2004-01-22 Aventis Pharma Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
ATE434602T1 (en) * 2002-09-25 2009-07-15 Novo Nordisk As METHOD FOR PRODUCING ACYLATED PEPTIDES
EP1543030A2 (en) 2002-09-25 2005-06-22 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
US20040157922A1 (en) 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en) 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
DE10258007B4 (en) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2509755A1 (en) 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20040242583A1 (en) 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
US7390814B2 (en) 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
US7652007B2 (en) 2003-02-13 2010-01-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
DE10306250A1 (en) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
DE10308351A1 (en) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments
DE10308353A1 (en) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (en) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments
DE10308355A1 (en) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
WO2004078195A1 (en) 2003-03-07 2004-09-16 Ajinomoto Co., Inc. Agent for converting intestinal cell into insulin-producing cell and remedy for diabetes
DK1605897T3 (en) 2003-03-19 2012-08-20 Lilly Co Eli POLYETHELEN-GLYCOL-LINK-GLP-1 compounds
WO2004087910A1 (en) * 2003-03-28 2004-10-14 National Institute Of Agrobiological Sciences Process for producing plant storage organ with high production of recombinant protein and novel recombinant protein
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
EP1618090A1 (en) 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
CA2523267C (en) 2003-04-23 2013-09-03 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101308912B1 (en) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
KR20060106812A (en) 2003-08-21 2006-10-12 노보 노르디스크 에이/에스 Isolation of Polypeptides Containing Racemized Amino Acids
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
RU2401276C2 (en) * 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
CN100444898C (en) * 2003-09-19 2008-12-24 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ATE525083T1 (en) * 2003-11-13 2011-10-15 Novo Nordisk As PHARMACEUTICAL COMPOSITION COMPRISING AN INSULINOTROPIC GLP-1(7-37) ANALOG, ASP(B28) INSULIN, AND A SURFACE-ACTIVE COMPOUND
PL1687019T3 (en) 2003-11-20 2018-05-30 Novo Nordisk A/S Peptide formulations containing propylene glycol that are optimal for production and for use in injection devices
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
JP2007514752A (en) 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス GLP-1 pharmaceutical composition
US7897566B2 (en) 2003-12-16 2011-03-01 Ipsen Pharma S.A.S. Analogues of GLP-1
MXPA06006745A (en) 2003-12-18 2006-08-18 Novo Nordisk As Novel glp-1 compounds.
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
PL1723128T3 (en) 2004-01-06 2013-04-30 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
BRPI0506694A (en) * 2004-01-08 2007-05-02 Theratechnologies Inc Long-acting glucagon-like peptide-1 analogs
RU2385879C2 (en) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Method of conjugating peptides, mediated by transglutaminase
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (en) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazole derivatives as inhibitors of the hormone sensitive lipase
KR100564618B1 (en) 2004-03-11 2006-03-28 삼성전자주식회사 How to Navigate Between Disk Drives
DE602004004631D1 (en) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolones, process for their preparation and their use as pharmaceuticals
GT200500063A (en) 2004-04-01 2005-10-14 METHOD FOR TREATMENT OF SCHIZOPHRENIA AND / OR GLUCOREGULATORY ABNORMALITIES
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
JP2008501765A (en) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Neutralization of drug-induced obesity using GLP-1 agonists
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
EP1789434B1 (en) 2004-08-31 2013-11-20 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP2330126B1 (en) 2004-10-07 2015-12-23 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
BRPI0517341A (en) * 2004-11-12 2008-10-07 Novo Nordisk As shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP1824835A1 (en) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
JP5410020B2 (en) 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス Insulin derivative
BRPI0608516A2 (en) 2005-03-18 2010-11-16 Novo Nordisk As glp-1 analog, method for increasing the time of action in a patient of a glp-1 analog, pharmaceutical composition, and use of a compound
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US7641649B2 (en) 2005-05-06 2010-01-05 Medtronic Minimed, Inc. Reservoir support and method for infusion device
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
JPWO2006126673A1 (en) * 2005-05-27 2008-12-25 第一三共株式会社 Antidiabetic drugs in combination
DE102005026762A1 (en) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
RU2412935C2 (en) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Phenoxyacetic acids as activators of delta receptors ppar
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
MX2008000255A (en) 2005-07-14 2008-04-02 Novo Nordisk As Urea glucokinase activators.
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
DE602005017628D1 (en) * 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusion polypeptides of glp-1 (glucagon-like peptide-1) with increased peptidase resistance
ES2393757T3 (en) 2005-11-17 2012-12-27 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
EA201101085A1 (en) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи PHENOXYACIC ACIDS AS PPAR DELTA ACTIVATORS
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US12070574B2 (en) 2006-02-09 2024-08-27 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
US12274857B2 (en) 2006-02-09 2025-04-15 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11027058B2 (en) 2006-02-09 2021-06-08 Deka Products Limited Partnership Infusion pump assembly
ATE524207T1 (en) 2006-02-09 2011-09-15 Deka Products Lp SYSTEMS FOR DISPENSING LIQUIDS
US12151080B2 (en) 2006-02-09 2024-11-26 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
ES2427247T3 (en) 2006-03-13 2013-10-30 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
WO2007115039A2 (en) 2006-03-30 2007-10-11 Valeritas, Llc Multi-cartridge fluid delivery device
PT2049475E (en) 2006-04-24 2012-04-12 Lilly Co Eli Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
BRPI0711370A2 (en) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3- (1,3-benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) pyridazine and its salts and solvates and their use as a histamine h3 receptor antagonist
DE102006028862A1 (en) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-amino-imidazo [1,2-a] pyridine
BRPI0715469A2 (en) 2006-07-11 2013-03-12 Qps Llc Pharmaceutical compositions for sustained release of peptides
US8071103B2 (en) 2006-07-18 2011-12-06 Centocor, Inc. Pharmaceutical composition comprising a human GLP-1 mimetibody
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
US7736338B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
ES2531934T3 (en) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Modified glycoproteins
CN101511364B (en) 2006-09-07 2012-08-15 奈科明有限责任公司 Combination treatment for diabetes mellitus
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8318778B2 (en) 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
DE102007002260A1 (en) 2007-01-16 2008-07-31 Sanofi-Aventis Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
JP2010517700A (en) 2007-02-09 2010-05-27 デカ・プロダクツ・リミテッド・パートナーシップ Automatic insertion assembly
DE102007008420A1 (en) 2007-02-21 2008-08-28 Merck Patent Gmbh benzimidazole derivatives
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
CA2685474C (en) 2007-04-30 2014-07-08 Medtronic Minimed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
WO2008149346A2 (en) 2007-06-04 2008-12-11 Ben Gurion University Of The Negev Research And Development Authority Enhanced sensitivity polymerase chain reactions
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
CN101743252A (en) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 Protease-stabilized, PEGylated insulin analogs
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
ES2550363T3 (en) 2007-09-05 2015-11-06 Novo Nordisk A/S Truncated GLP-1 derivatives and their therapeutic use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
BRPI0816798A2 (en) 2007-09-11 2016-10-11 Activx Biosciences Inc compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
CN102344457B (en) 2007-09-12 2015-07-22 杏林制药株式会社 Spirocyclic aminoquinolones as GSK-3 inhibitors
DE102007048716A1 (en) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo [1,2-a] pyrimidine derivatives
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
CN101861333A (en) 2007-11-16 2010-10-13 诺沃-诺迪斯克有限公司 Pharmaceutical composition comprising GLP-1 peptide or exendin-4 and basal insulin peptide
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP3679969A3 (en) 2007-12-31 2020-09-30 DEKA Products Limited Partnership Infusion pump assembly
CN110251769B (en) 2007-12-31 2022-04-01 德卡产品有限公司 Infusion pump assembly
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
JP5695909B2 (en) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Novel insulin derivatives with extremely delayed time action profiles
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
ES2613152T3 (en) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh New insulin derivatives with extremely delayed time / action profile
DE102008025008A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes
DE102008025007A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
US20110046071A1 (en) * 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
DE102008017590A1 (en) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CN101555214B (en) 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 Phenylcyclobutylamide derivatives and optical isomers, preparation methods and uses thereof
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5977945B2 (en) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Conjugate proteins with long-term in vivo efficacy
ES2561208T3 (en) 2008-09-12 2016-02-25 Novo Nordisk A/S Acylation method of a peptide or protein
EP2361105B1 (en) 2008-09-15 2021-06-02 DEKA Products Limited Partnership Systems and methods for fluid delivery
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
BR122013025625B1 (en) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL COMPOSITION, ITS USE AND METHOD OF PREPARATION OF THE SAME, KIT AND DEVICE
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
IT1392655B1 (en) 2008-11-20 2012-03-16 Bio Ker S R L SITE-SPECIFIC MONOCONJUGATED INSULINOTROPIC GLP-1 PEPTIDES.
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
JP5759379B2 (en) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド Neurotensin or neurotensin analog and use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20110126589A (en) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 Glucagon analogues
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
KR101593406B1 (en) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 Glucagon analogues
EP2370460B1 (en) 2008-12-15 2014-04-30 Zealand Pharma A/S Glucagon analogues
ES2542202T3 (en) 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Stable growth hormone compounds
JP5599822B2 (en) 2009-01-23 2014-10-01 ノヴォ ノルディスク アー／エス FGF21 derivatives having albumin binder ABCDE and their use
CN102942626B (en) * 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 Glucagon-like peptide-2 analog and its production and use
MX2011009414A (en) 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cycloalkylaminoquinolones as gsk-3 inhibitors.
CN102458376A (en) 2009-06-05 2012-05-16 Vero科学有限责任公司 Combination of dopamine agonists plus first phase insulin secretagouges for treatment of metabolic disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2014265118B2 (en) * 2009-06-05 2016-11-17 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EP2453948B1 (en) 2009-07-15 2015-02-18 DEKA Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
CN101987868B (en) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue
US8614182B2 (en) 2009-07-30 2013-12-24 Jiangsu Hansoh Pharmaceuticals Co., Ltd. GLP-1 analogues and their pharmaceutical salts and uses
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
EP2482823A2 (en) 2009-10-02 2012-08-08 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
HRP20150353T1 (en) 2009-11-13 2015-05-08 Sanofi-Aventis Deutschland Gmbh Pharmaceutical preparation containing GLP-1 agonist, insulin and methionine
ES2965209T3 (en) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising desPro36exendin-4(1-39)-Lys6-NH2 and methionine
MX2012006634A (en) 2009-12-16 2012-06-21 Novo Nordisk As Double-acylated glp-1 derivatives.
EP2525848B1 (en) 2010-01-22 2016-08-03 DEKA Products Limited Partnership System for shape-memory alloy wire control
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
US9422330B2 (en) * 2010-03-01 2016-08-23 Novo Nordisk A/S Preparative RP-HPLC method for purifying peptides
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
JP6054861B2 (en) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス New glucagon analogues
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP5827218B2 (en) 2010-04-30 2015-12-02 株式会社三和化学研究所 Peptides for improving in vivo stability, such as physiologically active substances, and physiologically active substances with improved in vivo stability
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
BR112012033225A2 (en) 2010-06-24 2017-06-20 Zealand Pharma As glucagon analogs
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
SI2611458T1 (en) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9278123B2 (en) 2010-12-16 2016-03-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN103298457A (en) 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 GLP-1 compositions
CN103298456A (en) 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 GLP-1 particles and compositions
BR112013018269A2 (en) 2011-01-20 2017-06-06 Zealand Pharma As combination of acylated glucagon analogs with insulin analogs
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd New oral dissolving films for insulin administration, for treating diabetes
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
BR112013026195A2 (en) 2011-04-12 2016-11-29 Novo Nordisk As double acylated glp-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
PT2750699E (en) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
CN103189389B (en) * 2011-09-03 2017-08-11 深圳市健元医药科技有限公司 New analogs of GLP I and its production and use
EP2753642B8 (en) 2011-09-06 2017-12-13 Novo Nordisk A/S Glp-1 derivatives
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2610175C2 (en) 2011-09-23 2017-02-08 Ново Нордиск А/С Novel glucagon analogues
TW201315742A (en) 2011-09-26 2013-04-16 Novartis Ag Bifunctional protein for the treatment of metabolic disorders
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
ES2562651T3 (en) 2011-10-04 2016-03-07 Sanofi-Aventis Deutschland Gmbh Lixisenatide for use in the treatment of stenosis or / and obstruction of the pancreatic duct system
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
EP2797947B1 (en) 2011-12-29 2018-05-02 Novo Nordisk A/S Dipeptide comprising a non-proteogenic amino acid
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
CN104220456B (en) 2012-02-15 2018-02-23 诺和诺德股份有限公司 With reference to and block myeloid cell express triggering acceptor 1 (TREM 1) antibody
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US11524151B2 (en) 2012-03-07 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2013139694A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
TR201802689T4 (en) 2012-05-03 2018-03-21 Zealand Pharma As Glucagon-like peptide-2 (glp-2) analogs.
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
JP6250034B2 (en) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス Double acylated GLP-1 derivative
ES2629735T3 (en) * 2012-05-08 2017-08-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
BR112014032938A2 (en) 2012-07-01 2017-08-01 Novo Nordisk As use of long-acting glp-1 peptides
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
JP6534927B2 (en) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ Glucagon analogue
FR2994848B1 (en) 2012-08-30 2014-08-22 Univ Paris Curie TREATMENT OF ARTHROSIS BY INCRETINED HORMONES OR THEIR ANALOGUES
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN103059127B (en) * 2013-01-07 2014-12-17 天津嘉宏科技有限公司 GLP-1 analogs, and preparation method and application thereof
DK2968471T3 (en) 2013-03-01 2017-10-23 Fundació Hospital Univ Vall D' Hebron - Inst De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, especially in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
EP2968443B1 (en) 2013-03-15 2021-09-29 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CN105120887A (en) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 Growth hormone compound formulation
MX362275B (en) 2013-04-18 2019-01-10 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use.
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CA2914977C (en) 2013-07-03 2021-11-02 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
CN105451776B (en) * 2013-08-15 2020-04-17 诺和诺德股份有限公司 GLP-1 derivatives and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
RS57632B1 (en) 2013-10-17 2018-11-30 Zealand Pharma As Acylated glucagon analogues
MX2016005995A (en) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compounds for the treatment of diabetes and disease complications arising from same.
TWI670281B (en) 2013-11-06 2019-09-01 西蘭製藥公司 Gip-glp-1 dual agonist compounds and methods
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
CN103884846B (en) * 2014-03-06 2016-06-08 杭州九源基因工程有限公司 A kind of detection method of Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] biologic activity
CN106132985B (en) * 2014-04-07 2020-10-13 诺和诺德股份有限公司 Double acylated GLP-1 compounds
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
EP3139948B1 (en) 2014-05-07 2020-03-04 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
CN113621027A (en) 2014-05-16 2021-11-09 领导医疗有限公司 Thioether peptide antagonists of alpha 4 beta 7 integrins
JP2017525656A (en) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス GLP-1 / glucagon receptor co-agonist for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104987383A (en) * 2014-07-08 2015-10-21 四川百利药业有限责任公司 GLP-1 derivate
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PE20170192A1 (en) 2014-07-17 2017-03-16 Novo Nordisk As MUTAGENESIS TARGETED TO THE TRIGGERING RECEPTOR ANTIBODY SITE EXPRESSED IN TYPE 1 MELOID (TREM-1) TO REDUCE VISCOSITY
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
RU2017114414A (en) 2014-10-01 2018-11-06 Протагонист Терепьютикс, Инк. NEW α4β7 ANTAGONISTS BASED ON MONOMERIC AND DIMERIC PEPTIDES
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN107001439B (en) 2014-10-29 2021-12-21 西兰制药公司 GIP agonist compounds and methods
EP3226906B1 (en) 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
MY181181A (en) 2014-12-23 2020-12-21 Novo Nordisk As Fgf21 derivatives and uses thereof
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
BR112017019378A2 (en) 2015-03-18 2019-02-19 Zealand Pharma A/S amylin analogs
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
ES2805743T3 (en) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Method and pharmaceutical composition for use in the treatment of diabetes
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3205660A1 (en) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of peptides with pswang linker
EP3405476B1 (en) 2016-01-20 2022-05-18 Polypeptide Laboratories Holding (PPL) AB METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3196206A1 (en) 2016-01-20 2017-07-26 Lonza Ltd Method for preparation of liraglutide
EP3205664A1 (en) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
JP7053480B2 (en) 2016-03-03 2022-04-12 ノヴォ ノルディスク アー／エス GLP-1 derivative and its use
WO2017149105A1 (en) 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in renal conditions
US20190070266A1 (en) 2016-03-04 2019-03-07 Novo Nordisk A/S Liraglutide in Diabetic Foot Ulcer
CA3018618A1 (en) 2016-03-23 2017-09-28 Bachem Holding Ag Method for preparing glucagon-like peptides
EP3433268B1 (en) 2016-03-23 2021-07-28 Bachem Holding AG Purification of glucagon-like peptide 1 analogs
CN109195618A (en) 2016-03-23 2019-01-11 领导医疗有限公司 Method for synthesizing 4 β of α, 7 peptide antagonists
AR109514A1 (en) 2016-09-09 2018-12-19 Zealand Pharma As AMILINE ANALOGS
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN110099719A (en) 2016-11-28 2019-08-06 诺和诺德股份有限公司 For improving glycemic control and reducing acute and long term diabetes complications moral paddy insulin
CN110022935A (en) 2016-11-28 2019-07-16 诺和诺德股份有限公司 Moral paddy insulin for the cardiovascular patient's condition
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
DK3551651T3 (en) 2016-12-09 2024-05-13 Zealand Pharma As ACYLATED GLP-1/GLP-2 DUAL ANTAGONISTS
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR102587196B1 (en) 2016-12-09 2023-10-10 질랜드 파마 에이/에스 GLP-1/GLP-2 dual agonist
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
JP2020514365A (en) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス Bicyclic compound capable of binding to melanocortin 4 receptor
WO2018210919A1 (en) 2017-05-17 2018-11-22 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11572399B2 (en) 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
PL3474820T3 (en) 2017-08-24 2024-05-13 Novo Nordisk A/S Glp-1 compositions and uses thereof
MA50233A (en) 2017-09-10 2020-07-22 Novo Nordisk As MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
TW201920234A (en) 2017-09-11 2019-06-01 美商領導醫療有限公司 Opioid agonist peptides and uses thereof
EP3728303A1 (en) 2017-12-19 2020-10-28 Novo Nordisk A/S Solubility of glp-1 peptide
CN118662611A (en) 2018-02-02 2024-09-20 诺和诺德股份有限公司 Solid composition comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) octanoic acid and a lubricant
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
RU2020128624A (en) 2018-02-27 2022-03-28 Зп Спв 3 К/С COMPSTATIN ANALOGUES AND THEIR MEDICAL APPLICATIONS
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
EP4122954B1 (en) 2018-04-05 2024-04-03 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (en) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
CA3098372A1 (en) 2018-04-24 2019-10-31 Deka Products Limited Partnership Apparatus and system for fluid delivery
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
TW201946930A (en) * 2018-05-15 2019-12-16 展旺生命科技股份有限公司 Preparation method of liraglutide derivative
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
EP3891174A1 (en) 2018-12-03 2021-10-13 Antag Therapeutics ApS Modified gip peptide analogues
EP3938037A1 (en) 2019-03-15 2022-01-19 Diet4Life ApS Combination of dietary peptides
WO2020201280A1 (en) 2019-04-01 2020-10-08 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
MX2022000397A (en) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
JP2022545916A (en) 2019-08-27 2022-11-01 セトペー エスペーベー ３ コマンディト セルスカブ Compstatin analogues and their medical uses
KR20220075343A (en) 2019-09-03 2022-06-08 프로타고니스트 테라퓨틱스, 인코포레이티드 Conjugated hepcidin mimetics
MA57599B1 (en) 2019-11-06 2024-06-28 Novo Nordisk A/S SEMAGLUTIDE FOR THE TREATMENT OF ALZHEIMER'S DEMENTIA
WO2021089752A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
CN111040022B (en) 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 Triple agonist targeting glucagon-like peptide-1 receptor, glucagon receptor, and gastric inhibitory peptide receptor
CA3166496A1 (en) 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
MX2022008740A (en) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
MX2022008741A (en) 2020-01-15 2022-10-03 Janssen Biotech Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
MX2022009844A (en) 2020-02-18 2022-09-05 Novo Nordisk As Glp-1 compositions and uses thereof.
EP4126003A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4142695A1 (en) 2020-04-29 2023-03-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
US20230173032A1 (en) 2020-05-07 2023-06-08 Frederiksberg Hospital Treatment of Hyperuricemia
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
EP4222176A4 (en) * 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
KR20230110570A (en) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. Compositions of Peptide Inhibitors of the Interleukin-23 Receptor
MX2023007788A (en) 2021-01-24 2023-11-17 Michael David Forrest ATP SYNTHASE INHIBITORS, COSMETIC AND THERAPEUTIC USES.
FR3120189B1 (en) 2021-03-01 2024-11-29 Farid Bennis Pharmaceutical composition for oral administration of a GLP-1 receptor agonist
CN113025675B (en) * 2021-05-21 2021-08-20 凯莱英医药集团（天津）股份有限公司 Process for producing polypeptide
WO2023285347A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
IL311166A (en) 2021-09-03 2024-04-01 Zealand Pharma As dosage regimen
KR20240056719A (en) 2021-09-08 2024-04-30 시오노기 앤드 컴파니, 리미티드 Medicines for the prevention and treatment of diseases involving anti-obesity effects
KR20240163156A (en) * 2022-03-28 2024-11-18 브리스톨-마이어스 스큅 컴퍼니 Macrocyclic immunomodulators
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
TW202421654A (en) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 Methods for treating obesity
EP4345104B1 (en) 2022-09-30 2024-08-28 Bachem Holding AG Method for preparing liraglutide
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20240176455A (en) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 Pharmaceutical formulations comprising a cyclodextrin
WO2024261076A1 (en) 2023-06-21 2024-12-26 Zealand Pharma A/S Weight loss
WO2024261259A1 (en) 2023-06-21 2024-12-26 Zealand Pharma A/S Analogues with improved properties
WO2025003471A1 (en) 2023-06-30 2025-01-02 Zealand Pharma A/S Combination therapy
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0587255A1 (en) 1986-05-05 1994-03-16 The General Hospital Corporation Insulinotropic hormone
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
DK36492D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As PREPARATION
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (en) * 1993-12-23 1993-12-23 Novo Nordisk As
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE59510951D1 (en) * 1994-10-21 2004-11-11 Nutrinova Gmbh Process for the cultivation of lipid-dependent tetrahymenides and a process for the production of biogenic materials from lipid-dependent tetrahymenides
DE122009000079I2 (en) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 DERIVATIVES

Also Published As

Publication number Publication date
DE69737479T4 (en) 2010-05-06
BRPI9711437B1 (en) 2017-05-16
EP0944648A1 (en) 1999-09-29
NO990950D0 (en) 1999-02-26
DE69737479T2 (en) 2007-11-29
DK0944648T3 (en) 2007-07-02
BR9711437A (en) 2000-01-18
BRPI9711437B8 (en) 2021-05-25
CA2468374C (en) 2010-12-21
PL192359B1 (en) 2006-10-31
NO325273B1 (en) 2008-03-17
ES2283025T3 (en) 2007-10-16
JP3149958B2 (en) 2001-03-26
PT944648E (en) 2007-06-26
EP0944648B1 (en) 2007-03-14
ATE356830T1 (en) 2007-04-15
CZ300837B6 (en) 2009-08-26
KR20000035964A (en) 2000-06-26
NO2009027I1 (en) 2009-11-30
DE69737479D1 (en) 2007-04-26
JP2006348038A (en) 2006-12-28
JP2000500505A (en) 2000-01-18
WO1998008871A1 (en) 1998-03-05
IL189136A0 (en) 2008-06-05
NL300422I1 (en) 2010-01-04
NO2019036I1 (en) 2019-09-20
AU3847897A (en) 1998-03-19
AU732957B2 (en) 2001-05-03
NL300422I2 (en) 2010-04-01
IL128332A0 (en) 2000-01-31
IL128332A (en) 2008-04-13
RU2214419C2 (en) 2003-10-20
IL189136A (en) 2015-05-31
PL331896A1 (en) 1999-08-16
UA72181C2 (en) 2005-02-15
JP2001011095A (en) 2001-01-16
DE122009000079I2 (en) 2011-06-16
EP1826216A1 (en) 2007-08-29
HUP9903714A3 (en) 2000-07-28
DE122009000079I1 (en) 2010-05-27
NO2009027I2 (en) 2015-01-19
KR100556067B1 (en) 2006-03-07
FR09C0054I2 (en) 2011-04-01
HUP9903714A2 (en) 2000-03-28
FR09C0054I1 (en) 2009-04-12
CN1271086C (en) 2006-08-23
CA2468374A1 (en) 1998-03-05
CN1232470A (en) 1999-10-20
NO990950L (en) 1999-04-28
AU732957C (en) 1998-03-19
CA2264243A1 (en) 1998-03-05
CZ62999A3 (en) 1999-07-14
HU227021B1 (en) 2010-05-28

Similar Documents

Publication Publication Date Title
CA2264243C (en) Glp-1 derivatives
EP1061946B1 (en) Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
US20110053839A1 (en) GLP-1 Derivatives II
US6268343B1 (en) Derivatives of GLP-1 analogs
EP1060191B1 (en) Derivatives of glp-1 analogs
US6458924B2 (en) Derivatives of GLP-1 analogs
US8097698B2 (en) Derivatives of GLP-1 analogs
CN1951965B (en) Glp-1 derivatives
AU3847897C1 (en) GLP-1 derivatives
EP1840134B1 (en) GLP-1 derivatives
MXPA99001823A (en) Glp-1 derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170822